US.JNJ · Johnson & Johnson

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 2,
      "details": {
        "atrPct": 1.9054729394217436,
        "turnoverUsdM": 2058.07705486497,
        "liquidityPoints": 0.8,
        "volatilityPoints": 1.2
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.JNJ",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 255.7186,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 2.5,
        "rsi_score": 2,
        "macd_score": 1.5,
        "volume_score": 2
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.3,
      "stop_loss_percent": 3.8,
      "take_profit_price": 279.1425,
      "target_multiplier": 1.9,
      "technical_strength": 1.85,
      "take_profit_percent": 5
    },
    "positionPoints": 2,
    "stopLossPoints": 2.4,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.3120102355054586,
    "stopLossPercent": 3.810945878843487,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 65.9,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 61.9,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 4
  },
  "market": {
    "ma20": 264.699,
    "ma50": 258.8922,
    "close": 265.85,
    "prevClose": 268.04,
    "avgVolume20": 6430270,
    "volumeRatio": 1.2,
    "changePercent": -0.82
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 4,
    "details": {
      "ret_5d": -0.026333133471292847,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 4,
      "vcp_bonus": 0,
      "vol_ratio": 1.2002302322011904,
      "ret_points": 0,
      "vol_points": 4,
      "range_ratio": 0.4931178438767892,
      "volat_points": 0,
      "day_range_pct": 0.009290953195751347,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 0,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 65.9,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 4.3,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 86,
        "contribution": 4.3
      },
      {
        "raw": 13.2,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 66,
        "contribution": 13.2
      },
      {
        "raw": 11.6,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 77.33,
        "contribution": 11.6
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 7.8,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 78,
        "contribution": 7.8
      },
      {
        "raw": 19,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 63.33,
        "contribution": 19
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "觀望",
    "result": 61.9,
    "details": [
      "基本面分析總分: 4.3/5分",
      "資金流分析總分: 13.2/20分",
      "市場環境分析總分: 11.6/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 7.8/10分",
      "技術信號分析總分: 19/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 4.3,
      "資金流": 13.2,
      "市場環境": 11.6,
      "情緒分析": 4,
      "技術信號": 19,
      "風險管理": 7.8
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "優秀",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.2,
          "epsPoints": 0.75,
          "roePoints": 0.75,
          "debtPoints": 0.5,
          "marginPoints": 0.6,
          "turnoverUsdM": 2058.07705486497,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0.3,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "一般",
        "items": {
          "cmfPoints": 2.4,
          "mfiPoints": 2.4,
          "obvPoints": 2.4,
          "vwapPoints": 4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.JNJ",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "良好",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 14.43
            }
          },
          "trend": {
            "score": 2.8,
            "details": {
              "qqq": {
                "ma20": 718.7765020000002,
                "ma50": 711.5868006399995,
                "name": "QQQ",
                "close": 716.76001,
                "points": 1.4
              },
              "spy": {
                "ma20": 769.6849949,
                "ma50": 754.36140122,
                "name": "SPY",
                "close": 767.049988,
                "points": 1.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 1.9054729394217436,
          "atrPoints": 4,
          "cciPoints": 2.4,
          "vixPoints": 2.4,
          "marketTrendPoints": 2.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 3,
              "sentimentScoreRaw": 0.9
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141302659,
                "url": "https://finnhub.io/api/news?id=388469ce8547a5d9a54c7c59bb87e7ceb8561ae8c9c41a8061496fe22685a3cc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE: JNJ) received European Commission approval for TECVAYLI®▼ (teclistamab) plus daratumumab for adults with relapsed or refractory multiple myeloma. The decision allows use of the combination as early as second line for patients whose disease has returned or is not responding to prior treatment. The approval is based on Phase 3 data that showed material improvements in patient outcomes versus existing standards of care. This adds another immunotherapy option to Johnson...",
                "category": "company",
                "datetime": 1787494085,
                "headline": "Johnson & Johnson (JNJ) Wins EU Approval For TECVAYLI Combo In Multiple Myeloma"
              },
              {
                "id": 141278134,
                "url": "https://finnhub.io/api/news?id=539c80438bdc4e697ed89aa10e944d59a448c1714225af37503e9183ae75da4a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "In the latest trading session, Johnson & Johnson (JNJ) closed at $267.37, marking a -2.21% move from the previous day.",
                "category": "company",
                "datetime": 1787265903,
                "headline": "Johnson & Johnson (JNJ) Registers a Bigger Fall Than the Market: Important Facts to Note"
              },
              {
                "id": 141278135,
                "url": "https://finnhub.io/api/news?id=159fe45d25dd0dd568eac487d39e684601b9b781ccd3b07bd95702c0db180199",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) is back in focus after its stock moved higher following a 6.6% rise in second quarter sales and an improved outlook for 2026. See our latest analysis for Johnson & Johnson. The recent second quarter update and regulatory news around Johnson & Johnson's MONARCH QUEST 3 system have come alongside strong momentum, with a 30 day share price return of 9.88% and an 81.38% total shareholder return over three years. This suggests investors have increasingly rewarded its...",
                "category": "company",
                "datetime": 1787260406,
                "headline": "Johnson & Johnson (JNJ) On Strong Results And 2026 Outlook Why Valuation Is Back In Focus"
              },
              {
                "id": 141237243,
                "url": "https://finnhub.io/api/news?id=7a80afc1beebf28007235ca103d8f206f6e4ab8468e2ba1548038609bd9fe248",
                "image": "https://www.chartmill.com/images/uploads/Best_Dividend_500_264px_webp_9524a3945f.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Johnson & Johnson passes ChartMill's Best Dividend Stocks screen with a high dividend rating, robust profitability, and solid health. A reliable income pick.",
                "category": "company",
                "datetime": 1786962687,
                "headline": "Johnson & Johnson (NYSE:JNJ): A Dividend Quality Standout"
              },
              {
                "id": 141212141,
                "url": "https://finnhub.io/api/news?id=b37de892ed668dadc063cca94c87fdf98a4674d68db4572b055b93442e76bb04",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The World Health Organization projects that the share of the world’s population aged 60 years and older will almost double from 12% in 2015 to 22% by 2050. The Population Reference Bureau expects the number of Americans aged 65 and older to climb from 58 million in 2022 to 82 million by 2050. The aging […]",
                "category": "company",
                "datetime": 1786662446,
                "headline": "Johnson & Johnson (JNJ)’s $5.5B Talc Settlement: Turning Point or Temporary Relief?"
              },
              {
                "id": 141200516,
                "url": "https://finnhub.io/api/news?id=16389bf6a4738707ea856c733b9d74175e963f8518fb7792090d6671148e0639",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE: JNJ) is advancing its novel antidepressant Seltorexant into late stage clinical development for major depressive disorder as a potential rapid acting treatment option. The company also entered a multi year partnership with ACCESS to expand adoption of advanced cardiac electrophysiology technologies in ambulatory surgery centers. Both moves align with Johnson & Johnson’s focus on higher growth therapeutic and medtech areas that are important for its long term...",
                "category": "company",
                "datetime": 1786551101,
                "headline": "Johnson & Johnson (JNJ) Advances Seltorexant And Expands Outpatient Cardiac Care"
              },
              {
                "id": 141189365,
                "url": "https://finnhub.io/api/news?id=3af242c14af2e122129a8e9419b3189b5d2cbedcadc8635aa37d3a59154b3ac7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "This healthcare giant is on a serious run, but with the stock trading at a peak, investors must decide if the powerful business engine has more fuel or if the price has already burned it all.",
                "category": "company",
                "datetime": 1786489797,
                "headline": "JNJ Keeps Climbing. Should You Climb On?"
              },
              {
                "id": 141180971,
                "url": "https://finnhub.io/api/news?id=e8e6381f9ed73fb35f8db6760f5729e3f0b640f006cf3deacd9def67d779bf36",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "In recent months, Johnson & Johnson reported strong Q2 2026 results, received FDA De Novo authorization for its OTTAVA soft-tissue robotic surgery system, advanced its RYBREVANT FASPRO oncology franchise with an FDA Priority Review, announced a US$5.50 billion talc settlement framework, and agreed to collaborate with Sail Biomedicines on in vivo CAR-T therapies. Together with leadership changes in its Innovative Medicine unit and new MedTech and electrophysiology partnerships, these...",
                "category": "company",
                "datetime": 1786407647,
                "headline": "What Johnson & Johnson (JNJ)'s OTTAVA FDA Win and Talc Deal Shift Mean For Shareholders"
              }
            ],
            "raw_source": [
              {
                "id": 141356225,
                "url": "https://finnhub.io/api/news?id=59a441525d8351f9ca682906e1f1184af38874463dd1c92a51d84c67a55ae7f7",
                "image": "",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "",
                "category": "company",
                "datetime": 1788188253,
                "headline": "Trump Admin To Target Biotechs With Curbs On Drug Pricing? What Investors Should Know"
              },
              {
                "id": 141355051,
                "url": "https://finnhub.io/api/news?id=d92b169b63df4d431d6ca4d3e2a910e2a44404564eff749693f603b009075ae3",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/466613278/image_466613278.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Big Pharma hits new 52-week highs on strong Q2 results; explore why some lag and which healthcare ETF offers best income risk/reward. Click for more and the picks.",
                "category": "company",
                "datetime": 1788173434,
                "headline": "Big Pharma's Comeback Is Here: Winners, Losers, And 4 ETFs"
              },
              {
                "id": 141341224,
                "url": "https://finnhub.io/api/news?id=a70f356816315e6c1cffbf3ddb6582552dedd39464f32f29f67f627611d5c738",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Dividend activity recap for Champions, Contenders & Challengers: dividend changes plus upcoming ex-dividend and pay dates. See more here.",
                "category": "company",
                "datetime": 1787954658,
                "headline": "Dividend Champion, Contender, And Challenger Highlights: Week August 30"
              },
              {
                "id": 141340370,
                "url": "https://finnhub.io/api/news?id=e708a3e3caeb62d314bc7aff88a96587fd102498e635e11de24aa36ba67757bd",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-stelara-pediatric-ulcerative-colitis",
                "category": "company",
                "datetime": 1787936718,
                "headline": "FDA Approves Stelara for Pediatric Ulcerative Colitis"
              },
              {
                "id": 141338793,
                "url": "https://finnhub.io/api/news?id=bd81a66323ddaec8a6c063ad55e9bab105eb706d36589a0de58b89f58003aded",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "https://www.who.int/news/item/28-08-2026-second-meeting-of-the-ihr-emergency-committee-on-the-epidemic-of-ebola-bundibugyo-virus-disease-in-the-democratic-republic-of-the-congo---meeting-report",
                "category": "company",
                "datetime": 1787921002,
                "headline": "World Health Organization Director General Determined That The Ebola Epidemic In DRC Still Meets Criteria Of Public Health Emergency Of International Concern, But Not Those Of A Pandemic Emergency"
              },
              {
                "id": 141336283,
                "url": "https://finnhub.io/api/news?id=d92db7b94ab38deb8d45bd11ce337de7df789b48d477823807203626cf4038b8",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2215519735/image_2215519735.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Dividend Aristocrats (NOBL) nearly match SPY in 2026, with top gainers, rising dividend growth, and 29 undervalued picks—see which to buy now.",
                "category": "company",
                "datetime": 1787894920,
                "headline": "Best Dividend Aristocrats For September 2026"
              },
              {
                "id": 141332096,
                "url": "https://finnhub.io/api/news?id=f91bace257ba0af744e76346de1ee986e0b1ace6e3fd1e564f4da44e81506cdf",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Stay updated with the movement of dow jones stocks in today's session. Discover which dow jones stocks are making waves on Thursday.",
                "category": "company",
                "datetime": 1787857806,
                "headline": "Thursday's session: top gainers and losers in the dow jones index"
              },
              {
                "id": 141331062,
                "url": "https://finnhub.io/api/news?id=5c23c716656d25f98d61da7895898b299ef98b2bd2a7cea04355a7c099030532",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Let's have a look at the top dow jones gainers and losers in the middle of the day of today's session.",
                "category": "company",
                "datetime": 1787848807,
                "headline": "Exploring the top movers within the dow jones index during today's session."
              },
              {
                "id": 141329551,
                "url": "https://finnhub.io/api/news?id=320a5de29203b8e44f2edf5548e3915f957e76feed78625c85f5fe1da7b57b64",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2217679967/image_2217679967.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "GSK stock outlook: FDA bepirovirsen Oct 26 decision, Phase 3 OCEAN results, and reaffirmed 2026 guidance. Read here for a detailed investment analysis.",
                "category": "company",
                "datetime": 1787818087,
                "headline": "GSK: Still One Of My Top Healthcare Picks"
              },
              {
                "id": 141324625,
                "url": "https://finnhub.io/api/news?id=45b7ccfee9169d8cf3dc418bd809f9b83e3e927cd7530f4e98fda7ca7f6a2c9d",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Stay informed about the performance of the dow jones index one hour before the close of the markets on Wednesday. Uncover the top gainers and losers in today's session for valuable insights.",
                "category": "company",
                "datetime": 1787771406,
                "headline": "Explore the top gainers and losers within the dow jones index in today's session."
              },
              {
                "id": 141325689,
                "url": "https://finnhub.io/api/news?id=4c11f9c85f6f5bafd7b1a79ae0b1c9c4a4769f2eeb503138a8fb922a2bc6b595",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/early-alert-heart-pump-controller-purge-cassette-issue-abiomed",
                "category": "company",
                "datetime": 1787752714,
                "headline": "FDA Issues Early Alert On Abiomed Heart Pump Controller Purge Cassette Issue"
              },
              {
                "id": 141317764,
                "url": "https://finnhub.io/api/news?id=4a58a6f746e24ff8c34ddff188f2b82ff0e1326f391c36ca862d996d0c19ac28",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Uncover the latest developments among dow jones stocks in today's session. Stay tuned to the dow jones index's top gainers and losers on Tuesday.",
                "category": "company",
                "datetime": 1787685007,
                "headline": "These dow jones stocks are moving in today's session"
              },
              {
                "id": 141317034,
                "url": "https://finnhub.io/api/news?id=a8858e98310f85462059e252bd76fc3444519de43c88f68833ab57142ce4739b",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Join us in exploring the top gainers and losers within the dow jones index in the middle of the day on Tuesday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1787676006,
                "headline": "Top dow jones movers in Tuesday's session"
              },
              {
                "id": 141318610,
                "url": "https://finnhub.io/api/news?id=9d4b621dd731c3bfdad3a47ce565844d36b00e614299f9ed8ee00b9c70737bcd",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/25/Exterior-Shot-Of-The-Johnson-Johnson-Cor.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Johnson & Johnson secured FDA approval for IMAAVY, the first targeted therapy to treat warm autoimmune hemolytic anemia in adults and youth.",
                "category": "company",
                "datetime": 1787646173,
                "headline": "Johnson & Johnson Secures FDA Approval For First Rare Anemia Treatment"
              },
              {
                "id": 141318611,
                "url": "https://finnhub.io/api/news?id=4ad21d2fea599cdc0d61b706eeab0eaff4b8a34cb50735c66e63a6b821fe3627",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "IMAAVY is an immunoselective FcRn blocker designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies while also preserving B-cell functionWarm autoimmune hemolytic anemia is a rare, life-threatening",
                "category": "company",
                "datetime": 1787628371,
                "headline": "Reported Earlier, FDA Approves Johnson & Johnson's IMAAVY (Nipocalimab-Aahu) As First-Ever Treatment For Warm Autoimmune Hemolytic Anemia, Based On Pivotal Phase 2/3 ENERGY Study"
              },
              {
                "id": 141310292,
                "url": "https://finnhub.io/api/news?id=51e21f3e9e89a69ade69beb2705a25f5ef509f927e49a56f97601ab66eb255f0",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders will",
                "category": "company",
                "datetime": 1787578524,
                "headline": "10 Health Care Stocks Whale Activity In Today’s Session"
              },
              {
                "id": 141308324,
                "url": "https://finnhub.io/api/news?id=d230e0ece83f4cba236cd869d85db24371c89847d296e0eca3524ccfa078799b",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1419068069/image_1419068069.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Sanofi stock faces temporary pressure after Trump’s vaccine order, but trades cheap (9.2x P/E) with raised 2026 guidance. Click for this SNY update.",
                "category": "company",
                "datetime": 1787561537,
                "headline": "Sanofi: Trump's Vaccine Policy Won't Break The Story"
              },
              {
                "id": 141307500,
                "url": "https://finnhub.io/api/news?id=32b08bbe296e7cb212fd1ae7c5aebca8ee10a12f8968f1cb43ac3b54896393a6",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2260312486/image_2260312486.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Dividend Kings beat the S&P 500 YTD, with 30 topping SPY and 25 looking undervalued with 10%+ return potential.",
                "category": "company",
                "datetime": 1787547151,
                "headline": "Best Dividend Kings: August 2026"
              },
              {
                "id": 141302662,
                "url": "https://finnhub.io/api/news?id=db2fb799a2d2b70f0dc9a338e3091164c1e667df826fe8a27b5a9e784c37657b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Reaching $6,600 a month in dividend income sounds like a single-number problem, but the capital you actually need swings by more than a million dollars depending on which yield tier you choose and what you give up to get there.",
                "category": "company",
                "datetime": 1787501181,
                "headline": "How to Build $6,600 a Month in Dividend Income From Three Income Buckets"
              },
              {
                "id": 141302658,
                "url": "https://finnhub.io/api/news?id=21d4ca7e74876b659e37383bc7de23d9ba6e82ab875bf3e225232bd910740850",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Collecting over $141,000 a year in dividends without selling a single share sounds like a fantasy until you realize the yield you chase determines whether your income grows, stagnates, or quietly cannibalizes itself.",
                "category": "company",
                "datetime": 1787497062,
                "headline": "How to Build $11,800 a Month in Dividend Income Without Selling a Single Share"
              },
              {
                "id": 141302659,
                "url": "https://finnhub.io/api/news?id=388469ce8547a5d9a54c7c59bb87e7ceb8561ae8c9c41a8061496fe22685a3cc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE: JNJ) received European Commission approval for TECVAYLI®▼ (teclistamab) plus daratumumab for adults with relapsed or refractory multiple myeloma. The decision allows use of the combination as early as second line for patients whose disease has returned or is not responding to prior treatment. The approval is based on Phase 3 data that showed material improvements in patient outcomes versus existing standards of care. This adds another immunotherapy option to Johnson...",
                "category": "company",
                "datetime": 1787494085,
                "headline": "Johnson & Johnson (JNJ) Wins EU Approval For TECVAYLI Combo In Multiple Myeloma"
              },
              {
                "id": 141302655,
                "url": "https://finnhub.io/api/news?id=03c4af49faa3248a17236f16e54e2ad52d8c77e6aaba2aa9c9e40e4f0b5480d3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Generating $19,000 a month from dividends alone sounds like a single problem with one answer, but the yield you chase changes the required nest egg by millions and introduces a completely different set of risks, tax consequences, and long-term tradeoffs.",
                "category": "company",
                "datetime": 1787489589,
                "headline": "The Portfolio Blueprint for Building $19,000 a Month in Dividend Income"
              },
              {
                "id": 141298697,
                "url": "https://finnhub.io/api/news?id=2d5710b92f04902e09f6d2f69fcfa2272cadf3005050fd3d2e8b7aefa776a146",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2290281189/image_2290281189.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) keeps a Buy rating as Q2 2026 sales jump and guidance rises.",
                "category": "company",
                "datetime": 1787437480,
                "headline": "Johnson & Johnson: Buy IMAAVY Label Expansion First And Continued CAPLYTA Sales Push"
              },
              {
                "id": 141302656,
                "url": "https://finnhub.io/api/news?id=eee277137691b8bb1f60da98e4923a7ce57c368a09a3cf7685292136d698180a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Starting yield and dividend growth pull $465,000 in two very different directions over a decade, and choosing the wrong one at 53 could cost you far more than the yield gap suggests.",
                "category": "company",
                "datetime": 1787417991,
                "headline": "How a 53-Year-Old Can Turn $465,000 Into a Monthly Paycheck Machine by 63"
              },
              {
                "id": 141278028,
                "url": "https://finnhub.io/api/news?id=b85cf2c4c1752d6b68a87ce0e31deed248fb731b2165e96279cc313ac08ca183",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Consensus asks Eli Lilly for far less growth than it is delivering, and for margins to keep climbing from a level it only just reached.",
                "category": "company",
                "datetime": 1787341256,
                "headline": "Lilly's Multiple Assumes Less Growth Than You Think"
              },
              {
                "id": 141272166,
                "url": "https://finnhub.io/api/news?id=2a96d4aa691194c3fc85b2b1ae496aa054a0278a839aae1dbc4db975bd1f5df7",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Wondering what's happening in today's session for the dow jones index? Stay informed with the top movers within the dow jones index on Friday.",
                "category": "company",
                "datetime": 1787339405,
                "headline": "Discover which dow jones stocks are making waves on Friday."
              },
              {
                "id": 141278131,
                "url": "https://finnhub.io/api/news?id=89e11e354106d0898435d7a254123a430d13cfd8b0f361ffc7ad70f19589620f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "With US procedure growth slowing and the shares well below their high, the operating margin has widened in each of the last three years.",
                "category": "company",
                "datetime": 1787338881,
                "headline": "Intuitive Surgical Stock Has Fallen While Its Operating Margin Keeps Widening"
              },
              {
                "id": 141278037,
                "url": "https://finnhub.io/api/news?id=2171816a642cf2107b69f459ff8b534241a7636c5e34d5621c3285981f97c7b3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "What AbbVie sells, and who pays for it, is the useful way to read its low correlation to the index.",
                "category": "company",
                "datetime": 1787338129,
                "headline": "Most Of What Moves AbbVie Stock Has Nothing To Do With The Market"
              },
              {
                "id": 141278122,
                "url": "https://finnhub.io/api/news?id=0977c52a95d29262be27b66940bfe9ff452324b5c75e183fd25e8696ac568783",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Healthcare stocks were higher Friday afternoon, with the NYSE Healthcare Index rising 1.4% and the S",
                "category": "company",
                "datetime": 1787337803,
                "headline": "Sector Update: Healthcare Stocks Advance in Afternoon Trading"
              },
              {
                "id": 141273578,
                "url": "https://finnhub.io/api/news?id=39359255fee6dd1beadb269dd99f2e2f1d0813d68dd4371fa931522e517ddb8d",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Get this week’s Dividend Champions, Contenders & Challengers update: dividend changes, upcoming ex-dividend dates, and pay dates. Read the full list here.",
                "category": "company",
                "datetime": 1787334897,
                "headline": "Dividend Champion, Contender, And Challenger Highlights: Week August 23"
              },
              {
                "id": 141278123,
                "url": "https://finnhub.io/api/news?id=9cae0317b65b6eba8d87665a1ecddead57b0139873dabf525dfd582092c9d215",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Halozyme stock jumps 36% in a month as strong ENHANZE-driven royalties and recently raised 2026 guidance boost investor confidence.",
                "category": "company",
                "datetime": 1787332980,
                "headline": "HALO Stock Rises 36% in a Month: Here's What You Should Know"
              },
              {
                "id": 141278125,
                "url": "https://finnhub.io/api/news?id=c4219d4c8cc06018c3099f6575c54f4f5c3fca8777f4943262f105bf447c2dec",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "JNJ's MONARCH QUEST 3 wins FDA 510(k) clearance, adding AI-powered planning, navigation and imaging upgrades for robotic bronchoscopy.",
                "category": "company",
                "datetime": 1787330580,
                "headline": "Johnson & Johnson Wins FDA 510(k) Clearance for MONARCH QUEST 3 Update"
              },
              {
                "id": 141270977,
                "url": "https://finnhub.io/api/news?id=8f9d28002ee9400803c1bc65f23e8d2596ad9b71d181614b5198d194aed28983",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Stay informed about the performance of the dow jones index in the middle of the day on Friday. Uncover the top gainers and losers in today's session for valuable insights.",
                "category": "company",
                "datetime": 1787330405,
                "headline": "Stay informed with the top movers within the dow jones index on Friday."
              },
              {
                "id": 141278133,
                "url": "https://finnhub.io/api/news?id=46096836229cd109886a31607450140798e778ceba0267ef93ba2d063409e8c2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "MRK's growing pipeline, acquired assets and new product launches are gaining traction as it builds a diversified growth base ahead of Keytruda's 2028 LOE.",
                "category": "company",
                "datetime": 1787324760,
                "headline": "Can Merck's New Drugs Offer Growth Cushion Ahead of Keytruda LOE?"
              },
              {
                "id": 141278126,
                "url": "https://finnhub.io/api/news?id=ebe5e461e4f5914b214b179ea12aa2bb4137857c500ea7d6ac2d3397935dd4c8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "JNJ's diversified portfolio and pipeline strength offer an edge over MRK as both face patent expiration challenges.",
                "category": "company",
                "datetime": 1787318820,
                "headline": "Merck vs. J&J: Which Healthcare Giant Should Investors Choose?"
              },
              {
                "id": 141278127,
                "url": "https://finnhub.io/api/news?id=5dadccaac1a006ef5bb2d2699d5418ad82ec3a26a87def6d58ae1eaa5fe4e738",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Approval is based on unprecedented Phase 3 data showing statistically significant improvements in progression-free and overall survival versus standard of care regimens1This immunotherapy doublet regimen demonstrated durable disease control as early as second line, with more than 90% of patients who were progression-free at six months remaining progression-free at three years1 BEERSE, BELGIUM, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced that the European Commission (EC) h",
                "category": "company",
                "datetime": 1787308800,
                "headline": "European Commission approves Johnson & Johnson’s TECVAYLI®▼ (teclistamab) plus daratumumab for relapsed/refractory multiple myeloma, offering a potential new standard of care"
              },
              {
                "id": 141278134,
                "url": "https://finnhub.io/api/news?id=539c80438bdc4e697ed89aa10e944d59a448c1714225af37503e9183ae75da4a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "In the latest trading session, Johnson & Johnson (JNJ) closed at $267.37, marking a -2.21% move from the previous day.",
                "category": "company",
                "datetime": 1787265903,
                "headline": "Johnson & Johnson (JNJ) Registers a Bigger Fall Than the Market: Important Facts to Note"
              },
              {
                "id": 141278135,
                "url": "https://finnhub.io/api/news?id=159fe45d25dd0dd568eac487d39e684601b9b781ccd3b07bd95702c0db180199",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) is back in focus after its stock moved higher following a 6.6% rise in second quarter sales and an improved outlook for 2026. See our latest analysis for Johnson & Johnson. The recent second quarter update and regulatory news around Johnson & Johnson's MONARCH QUEST 3 system have come alongside strong momentum, with a 30 day share price return of 9.88% and an 81.38% total shareholder return over three years. This suggests investors have increasingly rewarded its...",
                "category": "company",
                "datetime": 1787260406,
                "headline": "Johnson & Johnson (JNJ) On Strong Results And 2026 Outlook Why Valuation Is Back In Focus"
              },
              {
                "id": 141263725,
                "url": "https://finnhub.io/api/news?id=dfd1ab1771431dd4977c3660606f49ee58f6377693bed6cc3754ed3555c67ed0",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Uncover the latest developments among dow jones stocks in today's session. Stay tuned to the dow jones index's top gainers and losers on Thursday.",
                "category": "company",
                "datetime": 1787253006,
                "headline": "Which dow jones stocks are moving on Thursday?"
              },
              {
                "id": 141278041,
                "url": "https://finnhub.io/api/news?id=b6b8b6bb83ce7842471b2d3ff17fd226a74f65641d1cab1c940ba182d5fc7a99",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The products meant to offset the KEYTRUDA patent expiry were named, and two were already booking revenue, before the stock moved.",
                "category": "company",
                "datetime": 1787250436,
                "headline": "Merck Stock Ran On A Checklist Published In Advance"
              },
              {
                "id": 141278042,
                "url": "https://finnhub.io/api/news?id=a185f67366da2df6e04ff21b866c03090a3bb454dfce33b84acf2978013b48e7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The medicines Pfizer has launched and acquired are arriving at close to the scale of the revenue its expiring patents will take away.",
                "category": "company",
                "datetime": 1787248494,
                "headline": "Pfizer Stock Is A Race Between New Drugs And Old Patents"
              },
              {
                "id": 141278128,
                "url": "https://finnhub.io/api/news?id=6ae953c0c2a0889b6642fd3164e527ee58f54d9cc09703b5237c69b976de98ca",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson's new drugs may offset declining sales due to patent-protection losses.",
                "category": "company",
                "datetime": 1787242320,
                "headline": "Johnson & Johnson Just Sent Shareholders an Important 11-Word Message About Its Future"
              },
              {
                "id": 141278139,
                "url": "https://finnhub.io/api/news?id=fcd332a3e0e30fe8a0f7d63cb0a926be225e4bb853171cc00071bc6cf71d34d0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Seaport Therapeutics just went public with a prodrug platform that has attracted board members from two of the biggest neuroscience acquisitions in recent history. The question is whether the same giants who funded those deals are already circling for a third.",
                "category": "company",
                "datetime": 1787240431,
                "headline": "Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO"
              },
              {
                "id": 141262581,
                "url": "https://finnhub.io/api/news?id=f8a4cc739e42f118d751acb01d597927956e108b45fcd4eabc8bb91e6c7d373f",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2229232770/image_2229232770.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Stryker (SYK) rebounds with 9% organic growth in Q2 as key segments accelerate.",
                "category": "company",
                "datetime": 1787231457,
                "headline": "Stryker: The Sell-Off Creates A Better Entry Point, But Q2 Wasn't Perfect"
              },
              {
                "id": 141263972,
                "url": "https://finnhub.io/api/news?id=c214f7edde73e38268c28f3292e33e368242c402dff0bce82285ce82ed18e751",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "You do not expect a pharmaceutical giant with a $376 billion market cap to put up numbers that make growth investors blush. Yet over the last 12 months, Merck (MRK) handed investors an 80% return, lapping the S&P 500. The apex occurred yesterday, August 19, 2026, when the stock surged to all-time highs.",
                "category": "company",
                "datetime": 1787223588,
                "headline": "Why Is Merck Stock Still Undervalued After An 80% Surge?"
              },
              {
                "id": 141265019,
                "url": "https://finnhub.io/api/news?id=3efe1267e5f6f11310f69d408807179b90b236964e8bbc86180a9ae298656234",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The stock has stood out while the index has barely moved, but the number that matters for a portfolio is how little of its return comes from the market.",
                "category": "company",
                "datetime": 1787173696,
                "headline": "Johnson & Johnson Stock Runs On A Calendar The Market Does Not Set"
              },
              {
                "id": 141278141,
                "url": "https://finnhub.io/api/news?id=f9a21b5be4efd6c3499dc4de20ff1853c616d3d46fa5e2c4daf0a6b0846d3792",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "AbbVie's upside case now turns on one pending dosing change for the medicine that supplies close to a third of guided revenue, and management expects it to speed up sales.",
                "category": "company",
                "datetime": 1787172052,
                "headline": "Is AbbVie Stock About To Break Out Again?"
              },
              {
                "id": 141278142,
                "url": "https://finnhub.io/api/news?id=54387e120c80ab99f828bd23591ac62cb7c9dc15e4d34a4198920e21bfd966dd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Liquidia's Yutrepia is gaining traction, with $300.3M in first-half sales and nearly 30% of inhaled-market revenues in Q2.",
                "category": "company",
                "datetime": 1787168400,
                "headline": "Can Yutrepia's Strong Growth Drive Liquidia's PAH Expansion?"
              },
              {
                "id": 141278143,
                "url": "https://finnhub.io/api/news?id=1d3df2215833561fd1be2c6edc2abe71630998ac9a6498e48a23e158b2a81595",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Teva's stock gains reflect stronger branded drug growth, a strengthening pipeline and improving finances, but generics and debt remain key risks.",
                "category": "company",
                "datetime": 1787155560,
                "headline": "Teva Rises 17% YTD: Should You Buy, Sell or Hold the Stock?"
              },
              {
                "id": 141261690,
                "url": "https://finnhub.io/api/news?id=7a9607d856e0e82042b208f8482169a113e1eb6033cde411e37384ae17f4bbe1",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/19/Exterior-Shot-Of-The-Johnson-Johnson-Cor.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Johnson & Johnson secures FDA clearance for MONARCH QUEST 3 software, boosting robotic bronchoscopy accuracy with AI. new 3D imaging tools.",
                "category": "company",
                "datetime": 1787145019,
                "headline": "Johnson & Johnson Expands Robotic Bronchoscopy Push With AI, 3D Navigation Upgrade"
              },
              {
                "id": 141254214,
                "url": "https://finnhub.io/api/news?id=6bbfa9f61ccce2d3cc984bb6f300d2f9f1f2a250cc4104106d379b62a5afa61c",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/insider_trade_3.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "On August 18, it was revealed in an SEC filing that Jennifer Taubert, EVP at Johnson & Johnson (NYSE:JNJ) executed a significant exercise of company stock options.\nWhat Happened: Taubert, EVP at Johnson &",
                "category": "company",
                "datetime": 1787137275,
                "headline": "EVP At Johnson & Johnson Exercises Options Worth $2.38M"
              },
              {
                "id": 141253313,
                "url": "https://finnhub.io/api/news?id=2e1130e90380ab9807504bf240b0038a51a19924cdacc932dd13f4834b335bfb",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1688769969/image_1688769969.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Rumors of an AstraZeneca PLC-Bristol-Myers Squibb Company merger are cooling. Click here for risks and drug portfolio insights on BMY and AZN stock.",
                "category": "company",
                "datetime": 1787131330,
                "headline": "AstraZeneca Vs. Bristol-Myers Squibb: Who's The Better Bargain For Investors?"
              },
              {
                "id": 141254559,
                "url": "https://finnhub.io/api/news?id=bd02e536795f125fafff8ee1e984a424fa04f12051c32b8b212f5a03bae43852",
                "image": "https://image.cnbcfm.com/api/v1/image/108309663-1779278269382-gettyimages-2263306993-TARGET_EARNS.jpeg?v=1787094405&w=1920&h=1080",
                "source": "CNBC",
                "related": "JNJ",
                "summary": "The S&P 500 fell for a third session as elevated bond yields and oil kept stocks under pressure Tuesday. Tune in to CNBC Wednesday for BlackRock's Rick Rieder.",
                "category": "company",
                "datetime": 1787080023,
                "headline": "Wednesday's big stock stories: What’s likely to move the market in the next trading session"
              },
              {
                "id": 141246754,
                "url": "https://finnhub.io/api/news?id=c403cfdc8e76b95c2c482fae3fa9b3d407ffa166cf0ae935a0f4797898d64f03",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Stay updated with the movements of the dow jones index in the middle of the day on Tuesday. Discover which stocks are leading as top gainers and losers in today's session.",
                "category": "company",
                "datetime": 1787071206,
                "headline": "Which dow jones stocks are moving on Tuesday?"
              },
              {
                "id": 141244204,
                "url": "https://finnhub.io/api/news?id=e6bf7b78e031bbcb468b8823cda499b666ece9ead74075c85b9647263cd0d6bf",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2255337276/image_2255337276.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Rose's Income Portfolio yielding 5.6% reached an all-time value high for the third time in July and is up 12.11% YTD. Read more on the portfolio here.",
                "category": "company",
                "datetime": 1787020480,
                "headline": "5 Undervalued Winners Up To 6.8% And 15 Overvalued To Avoid Now"
              },
              {
                "id": 141243872,
                "url": "https://finnhub.io/api/news?id=61ee943e8a5ea86e0618df87089dc0f85d75957dfa74acbe00fae233eab250ca",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1367003806/image_1367003806.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Stryker is a MedTech compounder with 11% organic revenue growth and expanding margins. Click here to read why SYK stock is a Hold.",
                "category": "company",
                "datetime": 1787015863,
                "headline": "Stryker Corporation: Hold For Quality, Wait For The Dip"
              },
              {
                "id": 141240002,
                "url": "https://finnhub.io/api/news?id=ec0668889a4c1c71892f8037054930e2b4ad337fa2c786bae0c8ac483da2e41c",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Let's have a look at the top dow jones gainers and losers one hour before the close of the markets of today's session.",
                "category": "company",
                "datetime": 1786993806,
                "headline": "Discover which dow jones stocks are making waves on Monday."
              },
              {
                "id": 141238736,
                "url": "https://finnhub.io/api/news?id=b91ca1b80516fc75a10e9df868b364cf20cf41b442449092f5176ac5b0392a13",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Let's have a look at the top dow jones gainers and losers in the middle of the day of today's session.",
                "category": "company",
                "datetime": 1786984806,
                "headline": "Uncover the latest developments among dow jones stocks in today's session."
              },
              {
                "id": 141237243,
                "url": "https://finnhub.io/api/news?id=7a80afc1beebf28007235ca103d8f206f6e4ab8468e2ba1548038609bd9fe248",
                "image": "https://www.chartmill.com/images/uploads/Best_Dividend_500_264px_webp_9524a3945f.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Johnson & Johnson passes ChartMill's Best Dividend Stocks screen with a high dividend rating, robust profitability, and solid health. A reliable income pick.",
                "category": "company",
                "datetime": 1786962687,
                "headline": "Johnson & Johnson (NYSE:JNJ): A Dividend Quality Standout"
              },
              {
                "id": 141225892,
                "url": "https://finnhub.io/api/news?id=39c878c307b3cf307c98d1ab7e82660110ac435ef76ffc0d9ce4242fe02540ce",
                "image": "",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "",
                "category": "company",
                "datetime": 1786802320,
                "headline": "Johnson & Johnson: Quality, But It Doesn't Deserve A Mid-20s Multiple Right Now"
              },
              {
                "id": 141224230,
                "url": "https://finnhub.io/api/news?id=378bd32677ead84815eb5c03e6e3830b56b7b1e398114ef6ed1b456b3a5bcb95",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1503342678/image_1503342678.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "A SWAN income portfolio aims for consistent income, growth, and lower volatility through diversification and strategic planning. Read how to build one here.",
                "category": "company",
                "datetime": 1786781400,
                "headline": "How To Invest $100,000 In A Retiree's SWAN Income Portfolio"
              },
              {
                "id": 141218647,
                "url": "https://finnhub.io/api/news?id=d4dda3373c4983a5dd7479b3d8440550dc2ade68937fd177531c3dfdb331d43f",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Join us in exploring the top gainers and losers within the dow jones index one hour before the close of the markets on Friday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1786734606,
                "headline": "What's going on in today's session: dow jones movers"
              },
              {
                "id": 141217398,
                "url": "https://finnhub.io/api/news?id=9aa0c7405fb35fba6c170c4b0e6fb0522d03435cb57c024ebca3a1d82648d3f9",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Join us in exploring the top gainers and losers within the dow jones index in the middle of the day on Friday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1786725606,
                "headline": "Which dow jones stocks are moving on Friday?"
              },
              {
                "id": 141216725,
                "url": "https://finnhub.io/api/news?id=75b3ea82141ce5c2d9b288a912788b857b5a70b3f29d76f59065d6a21564acbb",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1282122168/image_1282122168.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Boston Scientific (BSX) stock: EP/WATCHMAN slowdown drives discount valuation. See why it’s a Buy—new launches, insider buying, cost savings.",
                "category": "company",
                "datetime": 1786705872,
                "headline": "Boston Scientific: A Deep Dive Into The Headwinds And Why I See A Recovery Ahead"
              },
              {
                "id": 141212141,
                "url": "https://finnhub.io/api/news?id=b37de892ed668dadc063cca94c87fdf98a4674d68db4572b055b93442e76bb04",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The World Health Organization projects that the share of the world’s population aged 60 years and older will almost double from 12% in 2015 to 22% by 2050. The Population Reference Bureau expects the number of Americans aged 65 and older to climb from 58 million in 2022 to 82 million by 2050. The aging […]",
                "category": "company",
                "datetime": 1786662446,
                "headline": "Johnson & Johnson (JNJ)’s $5.5B Talc Settlement: Turning Point or Temporary Relief?"
              },
              {
                "id": 141210844,
                "url": "https://finnhub.io/api/news?id=2bf736f8c82a4e2be8402c591dd67c6328e0044a4c9301341ce2ff92fa7cc5f8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Options price a band whose floor sits below anything the stock has touched in the past year, and the company's own recovery timetable lands after that window closes.",
                "category": "company",
                "datetime": 1786656117,
                "headline": "How Much More Can Boston Scientific Stock Move After Losing Half Its Value?"
              },
              {
                "id": 141210845,
                "url": "https://finnhub.io/api/news?id=497ad8db27d537e7401288c2c7927079eb372edb1d570a09065e25b7e4c9d1b1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Rolling $880,000 into a self-directed IRA sounds like a clean break from the 9-to-5, but generating $5,200 a month from that balance forces a choice between safety and survival that most retirement calculators never show you.",
                "category": "company",
                "datetime": 1786654981,
                "headline": "How a 64-Year-Old Turned an $880,000 401(k) Rollover Into a $5,200 Monthly Paycheck Without Buying an Annuity"
              },
              {
                "id": 141209294,
                "url": "https://finnhub.io/api/news?id=ba7f0f61c40ef0086168e3480bf5c9fdcd372d2ed6ea42a5732ae892200ade92",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The pharmaceutical giant just increased its dividend by 3.1%, now paying $5.36 a share annually.",
                "category": "company",
                "datetime": 1786648320,
                "headline": "Johnson & Johnson Has Increased Its Dividend for 64 Consecutive Years. Here's How Much $10,000 Invested Pays Annually."
              },
              {
                "id": 141207923,
                "url": "https://finnhub.io/api/news?id=88a90702b18759d550549111dea289f1d88362148d397438d1ad60ef07c20c75",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "AbbVie's growth engine is firing on all cylinders, but on its latest earnings call, analysts focused on whether the company can defend its turf and execute on its next big pipeline bet.",
                "category": "company",
                "datetime": 1786637411,
                "headline": "The Sharpest Exchanges From ABBV's Earnings Call"
              },
              {
                "id": 141205477,
                "url": "https://finnhub.io/api/news?id=41b3346ec67ad1f4ad86b0dc449930056d36b39e7e47683726bc6e3893cf0f7c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 and reported positive three-year data from Phase 1 AQUAx clinical trial evaluating AAV2-hAQP1 for the treatment of moderate to severe grade 2/3 radiation-induced xerostomia Completed the acquisition of all interests and rights to botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP) from Johnson & Johnson* (J&J) for $25 million Strengthened balance sheet with $100 million equity financing concu",
                "category": "company",
                "datetime": 1786622400,
                "headline": "MeiraGTx Reports Second Quarter 2026 Financial and Operational Results"
              },
              {
                "id": 141206335,
                "url": "https://finnhub.io/api/news?id=d62976004d42faff784e96ff18709f7d421ff45857c8e8cbc331ca79db7aab81",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/13/Doctor-Hand-Point-Patient-Lung-X-ray-Fil.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Cullinan Therapeutics and Taiho report positive Phase 3 trial results for zipalertinib in treating advanced lung cancer.",
                "category": "company",
                "datetime": 1786620105,
                "headline": "Cullinan Therapeutics Zipalertinib Combo Clears Key Phase 3 Hurdle As First-Line Lung Cancer Treatment Option Takes Shape"
              },
              {
                "id": 141200509,
                "url": "https://finnhub.io/api/news?id=e592376329a72805d9a9aeb76b4e614c74226f090c0ad68a111e0bb4d3e4df81",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Get paid a real income now on your Intuitive Surgical shares—income you keep no matter what—in exchange for agreeing to sell at a higher price if the stock gets there.",
                "category": "company",
                "datetime": 1786570649,
                "headline": "The Paid-To-Hold Play On ISRG Stock: A 12% Annualized Income"
              },
              {
                "id": 141200510,
                "url": "https://finnhub.io/api/news?id=3a4f37e9bb9be44c5b31a36dd018aad8cc0bef3e357de5ae535c60b164dcc0c2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Intuitive Surgical (ISRG) shook investors after reporting strong Q2 2026 revenue and earnings that beat expectations, while revealing slower U.S. procedure growth and rising competitive pressure from Johnson & Johnson and Chinese robotic surgery platforms. See our latest analysis for Intuitive Surgical. The Q2 surprise arrives after a tough stretch for Intuitive Surgical, with the share price down 28.6% year to date and the 1 year total shareholder return declining 16.1%. The recent 7 day...",
                "category": "company",
                "datetime": 1786569196,
                "headline": "Intuitive Surgical (ISRG) Beats On Q2 As Investors Ask If The Bull Case Is Priced In"
              },
              {
                "id": 141200401,
                "url": "https://finnhub.io/api/news?id=9f8326d5bf4c5cc8712afd3a3a64b28f795699272f51d641a706f97680ee3451",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The drugmaker's operating numbers are near the top of its class, but its stock performance is lagging the pack. Is the market seeing a risk that the fundamentals are missing.",
                "category": "company",
                "datetime": 1786567769,
                "headline": "How ABBV Stock Moved Away From Its Peer Group"
              },
              {
                "id": 141200512,
                "url": "https://finnhub.io/api/news?id=00bc77a193caee8506d9c2f7e49efdf6fa5f4b117ad9f052361cece75a324ba4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Management raised its full-year forecast, but the market seems to be asking for more than a higher target.",
                "category": "company",
                "datetime": 1786562251,
                "headline": "Amgen Stock And The Price Of A Promise"
              },
              {
                "id": 141200513,
                "url": "https://finnhub.io/api/news?id=c73a8f0475758d31cd448380b74cbbb1c57e712f593a1a9679b90a05f53a54ea",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Two healthcare giants, two very different dividend bets: one built on six decades of unbroken raises and a fortress balance sheet, the other dangling a fatter yield while racing to outrun its own blockbuster's collapse. Knowing which risk you are actually buying changes everything.",
                "category": "company",
                "datetime": 1786559422,
                "headline": "Johnson & Johnson vs AbbVie: Safe Dividend vs Higher Yield"
              },
              {
                "id": 141200514,
                "url": "https://finnhub.io/api/news?id=26115dcb89643ffe9ddf725edb926159cea0317a8a8a874e34930e18eb09dc90",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Consensus growth takes only a modest slice off the multiple, and the company has not yet set the instrument pricing that lands inside those two years.",
                "category": "company",
                "datetime": 1786555201,
                "headline": "Two Years Of Growth Barely Change What You Pay For Intuitive Surgical"
              },
              {
                "id": 141200500,
                "url": "https://finnhub.io/api/news?id=ff75988727fcba1e5d818840746487c01f069e154db33e9b2aabc87f756101ed",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Four dividend giants from energy and pharma quietly generate the bulk of HDV's income, but their balance sheets and payout coverage look nothing alike. Before trusting that 3% yield, it pays to know which checks are ironclad and which carry a hidden catch.",
                "category": "company",
                "datetime": 1786551148,
                "headline": "The Energy and Pharma Giants Quietly Funding HDV’s 3% Yield, and How Safe Each One Is"
              },
              {
                "id": 141200516,
                "url": "https://finnhub.io/api/news?id=16389bf6a4738707ea856c733b9d74175e963f8518fb7792090d6671148e0639",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE: JNJ) is advancing its novel antidepressant Seltorexant into late stage clinical development for major depressive disorder as a potential rapid acting treatment option. The company also entered a multi year partnership with ACCESS to expand adoption of advanced cardiac electrophysiology technologies in ambulatory surgery centers. Both moves align with Johnson & Johnson’s focus on higher growth therapeutic and medtech areas that are important for its long term...",
                "category": "company",
                "datetime": 1786551101,
                "headline": "Johnson & Johnson (JNJ) Advances Seltorexant And Expands Outpatient Cardiac Care"
              },
              {
                "id": 141200517,
                "url": "https://finnhub.io/api/news?id=07b0a0bf7a9dcaaadfb74ca6213177c3075993d2885f8ca39092b204d4e913c8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Investing.com -- Oppenheimer upgraded Intuitive Surgical to Outperform from Perform with a $500 price target in a note on Wednesday, arguing the company's strategy of \"Crowding Out Competitors\" is strategically smart.",
                "category": "company",
                "datetime": 1786539571,
                "headline": "Intuitive Surgical: Oppenheimer now bullish, sees competition being \"crowded out\""
              },
              {
                "id": 141200518,
                "url": "https://finnhub.io/api/news?id=78cd813b9ec063ef31be0d6d0b44ffefcc96b5fa0be5dba40387d36f5497337d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "RAS mutations fuel nearly a third of all cancers, and one biotech has quietly built the deepest late-stage pipeline targeting them. Now the biggest names in pharma are circling, and the math on who can actually write the check gets complicated fast.",
                "category": "company",
                "datetime": 1786539024,
                "headline": "Why Revolution Medicines May Be Big Pharma’s Next Takeover Target"
              },
              {
                "id": 141200519,
                "url": "https://finnhub.io/api/news?id=24829641f332e3eb02dac53a3ed12233a7723a96315a57d782297c99b7e59aa1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Oppenheimer argues Ottava and Hugo pose no near-term threat to da Vinci",
                "category": "company",
                "datetime": 1786537519,
                "headline": "Oppenheimer Sees $500 for Intuitive Surgical as Rivals Stall"
              },
              {
                "id": 141200520,
                "url": "https://finnhub.io/api/news?id=c65b94e0e43f9872242ec47658569bc36e250f115a7c36b06abfd22d6dc9d7be",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "CONSHOHOCKEN, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced it has appointed John C. Reed, M.D., Ph.D., to its Board of Directors. Dr. Reed currently serves as Executive Vice President, Innovative Medicine, Research & Development at Johnson & Johnson (“J&J”) and is a member of J&J’s Executive Committee, where he",
                "category": "company",
                "datetime": 1786536000,
                "headline": "Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors"
              },
              {
                "id": 141193278,
                "url": "https://finnhub.io/api/news?id=357ca417d488522e729cb4788731a4e9c2bf02f33e056d92c95bfe0f40e34f92",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1202854526/image_1202854526.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Intuitive Surgical (ISRG) stock analysis: Hold rating with $426.65 price target (+9% upside).",
                "category": "company",
                "datetime": 1786532243,
                "headline": "Intuitive Surgical: Priced For Precision"
              },
              {
                "id": 141189365,
                "url": "https://finnhub.io/api/news?id=3af242c14af2e122129a8e9419b3189b5d2cbedcadc8635aa37d3a59154b3ac7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "This healthcare giant is on a serious run, but with the stock trading at a peak, investors must decide if the powerful business engine has more fuel or if the price has already burned it all.",
                "category": "company",
                "datetime": 1786489797,
                "headline": "JNJ Keeps Climbing. Should You Climb On?"
              },
              {
                "id": 141190121,
                "url": "https://finnhub.io/api/news?id=6122dcbbe887770943e505b8e118b1a6814c928f257ef65b6a02dcccc21b63a2",
                "image": "",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "",
                "category": "company",
                "datetime": 1786485283,
                "headline": "Tracking AMG's Yacktman Asset Management Portfolio - Q2 2026 Update"
              },
              {
                "id": 141200522,
                "url": "https://finnhub.io/api/news?id=f0d51c7ab430a8d753995618c9da44e3d2e03deb47af505ce082f9d74ce6f8d8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "These stocks can help you withstand (almost) any storm.",
                "category": "company",
                "datetime": 1786485000,
                "headline": "The U.S. Labor Market Is Weakening. These 2 Dividend Stocks Look Built to Weather a Recession"
              },
              {
                "id": 141189366,
                "url": "https://finnhub.io/api/news?id=875b935af433bfa3030edf6eff7cc254c4ffb82289f22197cb75fd2f1a2404bd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Pfizer sent shareholders a fortune in cash, yet the stock fell far behind the market, forcing a hard question about what all that money truly bought.",
                "category": "company",
                "datetime": 1786484330,
                "headline": "$49 Billion In Payouts, A Lagging Stock: The PFE Trade-Off"
              },
              {
                "id": 141189535,
                "url": "https://finnhub.io/api/news?id=8b7ddc3ba19accdc7c3f8b168aa7e62c548c4d2b85b10b4bc213275a31351fec",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "High-yield ETFs built purely on yield rankings carry a hidden flaw that only shows up when it's too late, and one fund uses a decade-long dividend track record as a filter before yield ever enters the picture.",
                "category": "company",
                "datetime": 1786481297,
                "headline": "This 5.3% Monthly Payer Only Buys Stocks That Raised Dividends 10 Straight Years, It’s Up 18.5% in 2026"
              },
              {
                "id": 141200525,
                "url": "https://finnhub.io/api/news?id=9bd6de94561c5f9895f0a16d21318d11b3e108f3082cc2010fca44440741e616",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson has surged more than 50% in a year and now sits within striking distance of its 52-week high, but a closer look at the valuation, insider activity, and pipeline pressures raises a pointed question about who actually wins from here.",
                "category": "company",
                "datetime": 1786473051,
                "headline": "Johnson & Johnson Nearing 52-Week High: Buy, Sell or Hold?"
              },
              {
                "id": 141200526,
                "url": "https://finnhub.io/api/news?id=bb45ea9039c763833121ecfb68e434d16b3cf6fb8431480eca4c3f9568d605b6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Skyrizi and Rinvoq drive ABBV's Q2 growth, with strong sales, market-share gains and new indications supporting the immunology franchise.",
                "category": "company",
                "datetime": 1786467240,
                "headline": "How Much Did Immunology Drugs Contribute to AbbVie's Q2 Performance?"
              },
              {
                "id": 141200527,
                "url": "https://finnhub.io/api/news?id=c26f0c93d5ac13d1ee53f2b75881070c80f4c7f2f90f49190e34322cdd77efa1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Legend Biotech just posted a quarter that flipped a key narrative for LEGN shareholders, but with a CEO transition underway and the stock still down sharply over the past year, the real question is whether this momentum can last.",
                "category": "company",
                "datetime": 1786467026,
                "headline": "Legend Biotech Gains 6% on Q2 Earnings Beat as Adjusted EPS Doubles Consensus"
              },
              {
                "id": 141200528,
                "url": "https://finnhub.io/api/news?id=43b7700b45a73638a49c042ec837866828a15b04a4cd6839ebd11f3a98553acd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "J&J's growth, new drug launches and pipeline strength support the stock, despite patent, MedTech and legal headwinds.",
                "category": "company",
                "datetime": 1786453920,
                "headline": "J&J Trading Above 200- & 50-Day SMAs: Buy, Sell or Hold the Stock?"
              },
              {
                "id": 141181749,
                "url": "https://finnhub.io/api/news?id=f314c7059854892624f29f049cf6afa75d82e766cad9d724e33ec098e825fede",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Pulling $54,000 a year from a $950,000 rollover IRA sounds like a math problem, but the real trap is hidden in the yield tier you choose and what it quietly does to your principal over time.",
                "category": "company",
                "datetime": 1786417828,
                "headline": "How a 65-Year-Old Turned a $950,000 401(k) Rollover Into a $4,500 Monthly Paycheck Without Buying an Annuity"
              },
              {
                "id": 141180971,
                "url": "https://finnhub.io/api/news?id=e8e6381f9ed73fb35f8db6760f5729e3f0b640f006cf3deacd9def67d779bf36",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "In recent months, Johnson & Johnson reported strong Q2 2026 results, received FDA De Novo authorization for its OTTAVA soft-tissue robotic surgery system, advanced its RYBREVANT FASPRO oncology franchise with an FDA Priority Review, announced a US$5.50 billion talc settlement framework, and agreed to collaborate with Sail Biomedicines on in vivo CAR-T therapies. Together with leadership changes in its Innovative Medicine unit and new MedTech and electrophysiology partnerships, these...",
                "category": "company",
                "datetime": 1786407647,
                "headline": "What Johnson & Johnson (JNJ)'s OTTAVA FDA Win and Talc Deal Shift Mean For Shareholders"
              },
              {
                "id": 141180189,
                "url": "https://finnhub.io/api/news?id=328cfb139ab5465f3851efd62dfbb11509b58513062093c5cf9c4e71670002a5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Eli Lilly's growth is huge, but on its latest call, analysts tested whether the next chapter can possibly live up to the last one.",
                "category": "company",
                "datetime": 1786402912,
                "headline": "What Analysts Really Pressed LLY On This Quarter"
              },
              {
                "id": 141180197,
                "url": "https://finnhub.io/api/news?id=e1475054062b34cd1e579db6e30f51d53ff66584d8bd4898bca58b1dd1f00b49",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) delivered another strong quarter in fiscal Q2 2026, with reported sales increasing 6.6% year over year to $25.31 billion and surpassing analysts’ average estimate of around $25.05 billion. Adjusted earnings per share reached $2.90, also exceeding estimates of $2.85. The healthcare giant raised its full-year outlook and said it remains on […]",
                "category": "company",
                "datetime": 1786401417,
                "headline": "Johnson & Johnson vs. Medtronic: Which Healthcare Stock Is Better Positioned After Earnings?"
              },
              {
                "id": 141178849,
                "url": "https://finnhub.io/api/news?id=433997050bd2890e444cd9fe8c62f04199331016475b024c602a47f22951db8f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Turning 65 comes with a quiet IRS bonus most retirees overlook, and the way you deploy it in the next few months could determine whether your retirement generates real monthly cash or simply keeps pace with inflation.",
                "category": "company",
                "datetime": 1786397725,
                "headline": "The IRS Just Gave 65-Year-Olds a New $6,000 Deduction. These 3 ETFs Turn the Tax Break Into Monthly Income"
              },
              {
                "id": 141178443,
                "url": "https://finnhub.io/api/news?id=467e56f4b182ea0166c556f279995438e655e2910436bc540dd8e72bf1b2f623",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) delivered strong fiscal Q2 2026 results, with sales for the quarter growing nearly 7% to $25.31 ⁠billion, above analysts’ average estimate of about $25.05 billion. Adjusted earnings per share reached $2.90, surpassing the expectation of $2.85. The company also raised its guidance and stated that it is on track to meet […]",
                "category": "company",
                "datetime": 1786394999,
                "headline": "Johnson & Johnson vs Abbott Laboratories: Which Healthcare Giant Offers the More Compelling Growth Story After Earnings?"
              },
              {
                "id": 141178852,
                "url": "https://finnhub.io/api/news?id=0f33bd43e172eb07b895979288f411fc6b54b0ded3b402d9bd813ab5d1a1296b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Most 140-year-old companies are coasting. Johnson & Johnson (JNJ) is restructuring. And that's the part of the J&J story that rarely gets enough attention. When people think of this company, they think of dividend checks and baby powder. A steady, predictable blue-chip that you hold ...",
                "category": "company",
                "datetime": 1786393380,
                "headline": "140-year-old Dividend King eyes bold update to unlock new growth"
              },
              {
                "id": 141177545,
                "url": "https://finnhub.io/api/news?id=900a27fb3b4f315b53cc3d81f4180c5a0e7c3de6b57840523330bdfb92cad3d6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Two stalled franchises forced the guidance cut, and they sit outside the three quarters of revenue management still expects to grow at its long-run pace, with the shares now near the bottom of their decade on sales.",
                "category": "company",
                "datetime": 1786385693,
                "headline": "Boston Scientific Stock Is Priced As If WATCHMAN Were The Whole Company"
              },
              {
                "id": 141177536,
                "url": "https://finnhub.io/api/news?id=06f9855d2799e576a4ddc346eaf2e110f1bc1ef8bcee92747cb4ca2cb44668bc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "During the August 6 episode of CNBC’s Mad Money, Jim Cramer pointed to a growing sector rotation as portfolio managers look for innovation outside the mega-cap technology space. He said: Finally, tech had such a run that portfolio managers want exposure to other sectors of the market that still have innovation. Think of them as […]",
                "category": "company",
                "datetime": 1786385250,
                "headline": "Jim Cramer Highlights Pharmaceutical Giants as Non-Tech Innovation Plays Like JNJ and LLY"
              },
              {
                "id": 141176537,
                "url": "https://finnhub.io/api/news?id=3095480400af9b48e867b36c70234450d3fa5550b19fa7fb2d393ea7285a780c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Four stocks built on investment-grade balance sheets and decades of payout discipline could quietly generate thousands in annual passive income without requiring you to touch a thing after you buy them.",
                "category": "company",
                "datetime": 1786381214,
                "headline": "The “Set It & Forget It” Stocks I’d Want to Own"
              },
              {
                "id": 141176602,
                "url": "https://finnhub.io/api/news?id=9619ef377aa37b3295cafc7d2a4686061b76f5c87f4c8df7da46959859930693",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The case for more upside rests on its obesity pill, and what changed is not the drug but who can now write it and who can now pay for it.",
                "category": "company",
                "datetime": 1786377692,
                "headline": "Eli Lilly Stock's Next Climb Runs Through A Pill, Not Just An Injection"
              },
              {
                "id": 141177769,
                "url": "https://finnhub.io/api/news?id=9fc13a6f1f120c3d5712dbe2d97e5f0cc6fae4550b2463703edb7b77d3ef9238",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "https://youtu.be/H_RititNE8U",
                "category": "company",
                "datetime": 1786374019,
                "headline": "Trump Says Administration Recognizing Childhood Vaccine Recommendations For Only 11 Core Vaccinations; Hepatitis B, COVID-19, Influenza No Longer Recommended For All Children"
              },
              {
                "id": 141175263,
                "url": "https://finnhub.io/api/news?id=651fb21e318bc41ddae43d10d7c2453b96582a7b566b22793ffdf458b66e5630",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "ISRG's premium valuation faces scrutiny as strong Q2 growth, higher margins and expanding robotic platforms support its 2026 outlook.",
                "category": "company",
                "datetime": 1786372920,
                "headline": "ISRG Trades at a Premium P/E: Buy, Sell or Hold the Stock Now?"
              },
              {
                "id": 141180972,
                "url": "https://finnhub.io/api/news?id=b148dcf00323812f5b267054da70d27da72d802f94585b4c56c98206e3148ffa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Recently published Major Depressive Disorder Market Insights report includes a comprehensive understanding of current treatment practices, major depressive disorder emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].",
                "category": "company",
                "datetime": 1786372260,
                "headline": "Major Depressive Disorder Market is Predicted to Grow During the Forecast Period (2026-2036) as Novel Antidepressants are Expected to Enter the Market | DelveInsight"
              },
              {
                "id": 141174277,
                "url": "https://finnhub.io/api/news?id=c8b0be6128448ed6517a29d353ee86a9af7c0598f9d11c7fcacb0a597f3ab561",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) has officially entered the U.S. soft-tissue robotic surgery market after receiving FDA De Novo authorization for its OTTAVA robotic surgical system. The authorization represents an important milestone for J&J’s MedTech ambitions, but the company is entering a market in which Intuitive Surgical (NASDAQ:ISRG) already has an extensive installed base, established surgeon […]",
                "category": "company",
                "datetime": 1786365762,
                "headline": "Can Johnson & Johnson (JNJ) Challenge Intuitive Surgical (ISRG) After Ottava’s FDA Approval?"
              },
              {
                "id": 141173839,
                "url": "https://finnhub.io/api/news?id=cdede5a86a1a9c715bcc2916ec012ef4f51f2e1958b7fa818b04daf0ff357e39",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Healthcare just posted the best three-month run of any S&P 500 sector, yet two of the three biggest pharma names by market cap are still trailing the broader market. That gap between performance and fundamentals is creating a window that income and growth investors rarely see at the mega-cap level.",
                "category": "company",
                "datetime": 1786363255,
                "headline": "3 Beaten-Down Healthcare Stocks to Buy in August"
              },
              {
                "id": 141173661,
                "url": "https://finnhub.io/api/news?id=708790d3ed97aff81e6ad4135df1b3ec0ea28d48524b4b8d33e2223d77035f8c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "NEW YORK, August 10, 2026--ACCESS, through its physician-led group purchasing organization, ACCESS GPO, today announced a multi-year preferred portfolio agreement with Johnson & Johnson to support the adoption of advanced cardiac electrophysiology technologies in ambulatory surgery centers (ASC) across the United States. The agreement encompasses an integrated portfolio of three-dimensional mapping, intracardiac imaging, radiofrequency ablation and pulsed field ablation technologies.",
                "category": "company",
                "datetime": 1786359600,
                "headline": "ACCESS Announces Multi-Year Strategic Agreement to Bring Advanced Cardiac Electrophysiology Technologies to Ambulatory Surgery Centers"
              },
              {
                "id": 141174082,
                "url": "https://finnhub.io/api/news?id=e6ce91f5af34345df55033a4670541763ba669f9aa3ee976e2788077cf1ed33a",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/897600234/image_897600234.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Gilead’s 2026 outlook improves as R&D pipeline accelerates and Biktarvy & Livdelzi sales rise, lifting guidance.",
                "category": "company",
                "datetime": 1786353380,
                "headline": "Gilead Sciences: The Market May Be Underestimating Its Growth (Rating Upgrade)"
              },
              {
                "id": 141166521,
                "url": "https://finnhub.io/api/news?id=49b4eb0b58c7c8187f414179dca4fd12f413106bcf5509cfd5490c2536c733bd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The pharmaceutical icon's dividend yield has been pared back by the stock's recent rally, driven by a new growth initiative.",
                "category": "company",
                "datetime": 1786282500,
                "headline": "Johnson & Johnson Has Increased Its Dividend for 64 Consecutive Years. Here's How Much $10,000 Invested in the Dividend King Pays Annually."
              },
              {
                "id": 141165996,
                "url": "https://finnhub.io/api/news?id=d312ee22931520221c07d07121a1e44ae80a0359fab95e6c66061049a18e63e3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Retiring on dividends at 60 sounds straightforward until you realize the yield tier you choose today could mean the difference between an income stream that doubles over a decade and one that quietly erodes your nest egg.",
                "category": "company",
                "datetime": 1786271486,
                "headline": "How Much Do You Need Invested by 50 to Retire on Dividends at 60?"
              },
              {
                "id": 141163834,
                "url": "https://finnhub.io/api/news?id=682166d5a0f1e570f7f9aee03c9fe4069fcb59b09b1de9859d6aa55d18e2192d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A $425,000 nest egg can generate wildly different monthly paychecks depending on where you put it, but chasing the biggest number often destroys the very asset you need to last through your 70s.",
                "category": "company",
                "datetime": 1786241687,
                "headline": "How a 52-Year-Old Can Turn $425,000 Into a Monthly Paycheck Machine by 62"
              },
              {
                "id": 141163533,
                "url": "https://finnhub.io/api/news?id=3b7a86f6ceb88fe11df34224171d2e64d74b5e8b7d5f7a718f923ea58fe91d9c",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1160013511/image_1160013511.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Tweedy Browne’s Q2 2026 13F: $1.32B portfolio, top holdings & new Zoetis stake, plus trims/exits and concentration insights—read now.",
                "category": "company",
                "datetime": 1786229949,
                "headline": "Tracking Tweedy Browne Portfolio - Q2 2026 Update"
              },
              {
                "id": 141161631,
                "url": "https://finnhub.io/api/news?id=d6c260cfc31245fdd42fea1c704de11335f3671395d82b9923f7dfe0c3658652",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Replicating a Social Security check with dividends sounds straightforward until you realize the yield you chase determines whether your income grows, stalls, or quietly disappears over the next two decades.",
                "category": "company",
                "datetime": 1786225028,
                "headline": "How Much Do You Need Invested to Out-Earn the Average Social Security Check With Dividends?"
              },
              {
                "id": 141159772,
                "url": "https://finnhub.io/api/news?id=e886dd9a371b1193cc20166cfff1c8eb46fbec57659ce18470ef42e953cbf51c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Intuitive Surgical is a leader in the surgical robotics space, with a large installed base and strong recurring revenues.",
                "category": "company",
                "datetime": 1786206900,
                "headline": "Competition Is Heating Up, but Here's Why Intuitive Surgical Might Still Be the Smartest Bet in MedTech"
              },
              {
                "id": 141159811,
                "url": "https://finnhub.io/api/news?id=05df3d3befb27fcbb17ef36cacc91a682f255168ac4bdf4b964ea6b23fe250b3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Consumer sentiment is flashing recession warnings, yet three blue-chip dividend legends are quietly building cases for returns that would shock most defensive investors heading into 2027.",
                "category": "company",
                "datetime": 1786204853,
                "headline": "Why PG, JNJ, and KO Could Surprise Investors Next Year"
              },
              {
                "id": 141154726,
                "url": "https://finnhub.io/api/news?id=8eb35d291a41aabd6eece6f85806825baf60b71ccdaf5e1050319dc0a5f39099",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Chasing a $50,000 monthly dividend stream sounds like a math problem, but the yield you pick determines whether your portfolio funds four decades of freedom or quietly cannibalizes itself while the checks keep arriving.",
                "category": "company",
                "datetime": 1786152926,
                "headline": "The Portfolio Blueprint for Building $50,000 a Month in Dividend Income"
              },
              {
                "id": 141153742,
                "url": "https://finnhub.io/api/news?id=837899412ca90fb440861401f61ce0c54a661cfb43a0e5c8b1ba038ae6be9f54",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A $1.25 million nest egg can fund a very different retirement depending on one number: your withdrawal yield. The gap between a conservative dividend portfolio and an aggressive one swings your annual income by tens of thousands of dollars, but the safer-looking choice does not always win.",
                "category": "company",
                "datetime": 1786143956,
                "headline": "The 4% Rule vs. a Dividend Paycheck: Which Makes $1.25 Million Last Longer?"
              },
              {
                "id": 141154842,
                "url": "https://finnhub.io/api/news?id=3b927a14a18d57bb82a7fd5ecacd77c7fce9a6ee9183da869696a924d72adf22",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/186805810/image_186805810.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Fisher Asset Management’s Q2 2026 13F: portfolio up to $336B, top holdings, and biggest buys/sells (NVDA, AAPL, GE, UNH). See more details here.",
                "category": "company",
                "datetime": 1786140337,
                "headline": "Tracking Ken Fisher's Fisher Asset Management Portfolio - Q2 2026 Update"
              },
              {
                "id": 141150997,
                "url": "https://finnhub.io/api/news?id=88a39dba7b46c9ef3532a3dacaadb34f762c2eaa8d0111425bd83883fd42361a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE: JNJ) agreed to a US$5.5b settlement to resolve tens of thousands of talc baby powder lawsuits. The deal ends decades of litigation over alleged health risks tied to the company’s talc-based products. The settlement follows years of high profile trials and failed bankruptcy attempts related to the talc claims. This resolution removes a long running legal overhang and brings more clarity for Johnson & Johnson investors. Consider broadening your research to other large...",
                "category": "company",
                "datetime": 1786129835,
                "headline": "Johnson & Johnson (JNJ) Reaches $5.5 Billion Talc Settlement To Close Years Of Lawsuits"
              },
              {
                "id": 141150983,
                "url": "https://finnhub.io/api/news?id=dd12bcdfe4ed22cf3954c88504072df39a69214fa699b7fae9f00c2150af3b44",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "If you hold shares, you're already exposed to a potential future where the stock is either far higher or far lower, and the options market is pricing both as real possibilities.",
                "category": "company",
                "datetime": 1786127896,
                "headline": "The Two Divergent Paths Priced Into Eli Lilly Stock"
              },
              {
                "id": 141150999,
                "url": "https://finnhub.io/api/news?id=509d1b4e952a0aeb474cd891233e81de9defb913e5af7921abf668250c52c38b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "HALO's Q2 earnings and revenues surpass estimates, fueled by higher royalties and product sales. The company raises its 2026 outlook.",
                "category": "company",
                "datetime": 1786124100,
                "headline": "Halozyme's Q2 Earnings Beat Estimates, 2026 Outlook Raised, Stock Up"
              },
              {
                "id": 141149443,
                "url": "https://finnhub.io/api/news?id=efb02afd95a4d4bc4ee226799cdff5c5fa0f0c035cc81c9016c3c2934a836918",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Higher Darzalex and Kesimpta royalties supported a $195 million increase in Genmab's annual revenue-guidance midpoint.",
                "category": "company",
                "datetime": 1786121030,
                "headline": "Genmab Stock Rises 4.4% as Drug Royalties Lift Outlook"
              },
              {
                "id": 141149444,
                "url": "https://finnhub.io/api/news?id=6eddaf1405e0e388cadbb270d6f42e6d8ab67dd57e1aef96c841dd4f8e40e7ad",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.",
                "category": "company",
                "datetime": 1786117503,
                "headline": "Johnson & Johnson (JNJ) Could Be a Great Choice"
              },
              {
                "id": 141147642,
                "url": "https://finnhub.io/api/news?id=dee3bfaaa26dd1dc193bc2041ad8205d4e968a745c8d4b9c46d64ec0a8da856c",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/07/Jim-Cramer.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Jim Cramer praises Lockheed Martin and Ameriprise Financial, advises against Cipher Digital. Eli Lilly to acquire AtaiBeckley for $3.8B.",
                "category": "company",
                "datetime": 1786090497,
                "headline": "Jim Cramer Calls This Industrial Stock ‘Sensational’ And Ameriprise Financial ‘Fantastic’"
              },
              {
                "id": 141145315,
                "url": "https://finnhub.io/api/news?id=9bae148d509e15f33f7c7f51b19fd67204c196c2d20cb8ca78f4bd03fce69324",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Cooper Cos. could get a pop from the sale of a surgical unit. What two activists are up to in the stock.",
                "category": "company",
                "datetime": 1786084200,
                "headline": "This Contact Lens Stock Looks Ready to Rally"
              },
              {
                "id": 141144606,
                "url": "https://finnhub.io/api/news?id=c5d21850e45b332b8a9f633b2086e774a8eee721923745bc549ddc740937164a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "A mix of high expectations, profit-taking, and a slight dip in valuations has sent S&P 500 stocks sputtering even after solid earnings reports.",
                "category": "company",
                "datetime": 1786077000,
                "headline": "Earnings Have Been Excellent. Why Stocks Aren’t Showing It."
              },
              {
                "id": 141140378,
                "url": "https://finnhub.io/api/news?id=18dda5449409ddae05e01767ef3fab745104cac931f72401346faf528964fd1f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The number that separates a comfortable retirement from a perpetual side hustle depends entirely on which yield tier you trust with your capital, and the answer surprises most income investors who assume bigger payouts always win.",
                "category": "company",
                "datetime": 1786048558,
                "headline": "How to Build $8,500 a Month in Dividend Income Without Selling a Single Share"
              },
              {
                "id": 141140379,
                "url": "https://finnhub.io/api/news?id=cdb85452f719857131038c097e97d3a481eb0db071fdd1b61d571fffb88433c3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson and Johnson just committed over a billion dollars to flood the market with American-made contact lenses, but retirees banking on Medicare to share the cost are about to get a rude awakening at the pharmacy counter.",
                "category": "company",
                "datetime": 1786039338,
                "headline": "Johnson & Johnson Is Spending $1 Billion to Make More Contact Lenses. Medicare Covers Them in Only One Narrow Situation."
              },
              {
                "id": 141137156,
                "url": "https://finnhub.io/api/news?id=2f69e9460fe0aae9ead0dc803c5110b49010b128ce55b4a38234a0a34db793d9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "ABBV falls after cutting its 2026 EPS outlook to reflect the Apogee deal, despite strong Q2 results, higher revenue guidance and growth from key medicines.",
                "category": "company",
                "datetime": 1786031340,
                "headline": "ABBV Stock Dips 4% Despite Robust Q2: Buy the Dip or Stay Cautious?"
              },
              {
                "id": 141151000,
                "url": "https://finnhub.io/api/news?id=f6b95f7a6a09cda3c0c4b7d455d671b89a0612fd8928faa54a689befe343aef7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "With the 10-year Treasury yield near 4.70%, dividend stocks face a real test of relevance, and only a handful of names have the streak length and earnings power to still make the cut right now.",
                "category": "company",
                "datetime": 1786014038,
                "headline": "5 Solid Dividend Stocks to Buy in August"
              },
              {
                "id": 141135282,
                "url": "https://finnhub.io/api/news?id=640b1409a72503d9e6f1bc074056e39c7f7a8172eeeb828304077a865221e6fc",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Guggenheim  analyst Vamil Divan   maintains Johnson & Johnson (NYSE:JNJ) with a Buy and raises the price target from $270 to $287.",
                "category": "company",
                "datetime": 1786008177,
                "headline": "Guggenheim Maintains Buy on Johnson & Johnson, Raises Price Target to $287"
              },
              {
                "id": 141135283,
                "url": "https://finnhub.io/api/news?id=61b54d952a72f4dae3b74529ad2a238f7f8fa29b096a0fde8d3c13db7000a809",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/06/Valhalla--Ny--Usa---May-10--2023-Governo.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Kathy Hochul says Trump's Medicare subsidy decision will raise prescription drug costs for 1.3 million New Yorkers.",
                "category": "company",
                "datetime": 1785987665,
                "headline": "Kathy Hochul Slams Trump Over Medicare Cut, Says 1.3 Million New Yorkers Will Pay More for Prescriptions: 'A New Assault on Seniors...'"
              },
              {
                "id": 141127414,
                "url": "https://finnhub.io/api/news?id=70b784d51037fc27f530c0693cd7ca54aaa42aced8229c9033418c5edab4fcf2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The market is pricing in an unusually high cash-generation yield for one of the world's largest drugmakers, forcing investors to decide if the price reflects a temporary problem or a permanent decline.",
                "category": "company",
                "datetime": 1785964991,
                "headline": "Why PFE Stock Hands You So Much Cash Right Now"
              },
              {
                "id": 141127103,
                "url": "https://finnhub.io/api/news?id=74f1d8605d97be663e506ecf981a9be784dece7f365a97b32d92395aa6736c2a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "An 8% yield looks like a shortcut to $80,000 a year without selling a single share, but the brokerage account tells a different story than the headline number does.",
                "category": "company",
                "datetime": 1785964278,
                "headline": "The Dividend Income Illusion: Why Your 8% Yield Is Really Paying You 5%"
              },
              {
                "id": 141125722,
                "url": "https://finnhub.io/api/news?id=110153332401d9a1fcf4d26bc4b90e854967bae5d40d3b231943c9bd82b6aa37",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Royalty Pharma PLC (RPRX) reports 14% total receipts growth and raises full-year 2026 guidance for the second consecutive quarter.",
                "category": "company",
                "datetime": 1785956489,
                "headline": "Royalty Pharma PLC (RPRX) (Q2 2026) Earnings Call Highlights: Strong Growth and Raised Guidance"
              },
              {
                "id": 141125723,
                "url": "https://finnhub.io/api/news?id=26cfbf22c1faa2f249fc084445c5ac688bc9101b4b9ef126b866c864aacdbd83",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Compass Pathways PLC (CMPS) reports $433 million in cash and advances rolling NDA submission for COMP360 in treatment-resistant depression, targeting a first-half 2027 launch.",
                "category": "company",
                "datetime": 1785956483,
                "headline": "Compass Pathways PLC (CMPS) (Q2 2026) Earnings Call Highlights: Strong Cash Position and NDA ..."
              },
              {
                "id": 141124166,
                "url": "https://finnhub.io/api/news?id=2b58a2b70a614fd7eb95675fb60fa6b620b990c4eed234103bd5771f1f2ae0fc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "LLY crushes Q2 earnings estimates and lifts its 2026 sales outlook as Mounjaro and Zepbound fuel strong revenue growth and newer drugs add momentum.",
                "category": "company",
                "datetime": 1785946020,
                "headline": "LLY Q2 Earnings Top, GLP-1 Drugs Fuel Growth, Sales Guidance Raised"
              },
              {
                "id": 141124190,
                "url": "https://finnhub.io/api/news?id=ef66cdca1edae98df18b0c5ebc62b1879e71fd41b3c066690822a1c935a99bcb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Boston Scientific's cheaper valuation offers upside, but weaker guidance, share losses, higher debt and delayed catalysts favor patience.",
                "category": "company",
                "datetime": 1785945060,
                "headline": "Should Investors Buy Boston Scientific Stock Despite Near-Term Risks?"
              },
              {
                "id": 141119729,
                "url": "https://finnhub.io/api/news?id=bccb2c1b68ad383e4caedda432b8139db37db17d83898169bb7534530ed6d896",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Annuity payouts are the most competitive they have been in years, which makes the timing of this comparison unusually consequential for anyone sitting on a $675,000 nest egg and trying to decide which structure actually puts more money in their pocket for life.",
                "category": "company",
                "datetime": 1785921004,
                "headline": "Dividends vs. an Annuity: Which Turns $675,000 Into More Monthly Income for Life?"
              },
              {
                "id": 141119247,
                "url": "https://finnhub.io/api/news?id=b669c46b5cc4c6fb2b18b34700e8b7efa67cc72776645a8e7f74e02762389ae1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) is back in focus after longtime executive Jennifer Taubert retired as Executive Vice President, Worldwide Chairman, Innovative Medicine, with experienced biopharmaceutical leader Tom Cavanaugh set to succeed her. See our latest analysis for Johnson & Johnson. Johnson & Johnson’s share price has had a strong run in 2026, with a year to date share price return of 22.95% and a 90 day share price return of 13.49%, while the 1 year total shareholder return of 53.04%...",
                "category": "company",
                "datetime": 1785910222,
                "headline": "Johnson & Johnson (JNJ) Could Be 10% Overvalued Following Leadership Change"
              },
              {
                "id": 141116445,
                "url": "https://finnhub.io/api/news?id=760ff458c72ca13720f443f594d6629cbea45237b6d479e30ca7d32fe7bf3512",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Replacing a six-figure salary with dividends is a math problem first, and the capital requirement swings by more than a million dollars depending on one variable most investors treat as an afterthought.",
                "category": "company",
                "datetime": 1785887008,
                "headline": "How Much Do You Really Need Invested to Replace a $100,000 Salary With Dividends?"
              },
              {
                "id": 141113185,
                "url": "https://finnhub.io/api/news?id=ffe8f821463a343289a11f64068bcee41cc91dca55356f4a3d50ffb074e8f0f3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The healthcare giant showered its owners with cash, yet the stock fell behind. Here is the accounting of what investors actually got and what the trade-off cost them.",
                "category": "company",
                "datetime": 1785871390,
                "headline": "The $85 Billion Consolation Prize For JNJ Shareholders"
              },
              {
                "id": 141110788,
                "url": "https://finnhub.io/api/news?id=30905f0760c72cb9500a521fd9bc31fde32949ac88ad843d045fab1c8fb20a6c",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Join us in exploring the top gainers and losers within the dow jones index in the middle of the day on Tuesday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1785861604,
                "headline": "Tuesday's session: top gainers and losers in the dow jones index"
              },
              {
                "id": 141111661,
                "url": "https://finnhub.io/api/news?id=dbc807d21170ae2868706b1631043043e40b2bab62008ddb8ae49e512e665fbc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Bayer tops Q2 estimates as Crop Science and fast-growing drugs offset pressure from patent-expired brands, while reaffirming its 2026 outlook.",
                "category": "company",
                "datetime": 1785859020,
                "headline": "BAYRY Beats on Q2 Earnings, Crop Science Business Boosts Growth"
              },
              {
                "id": 141109856,
                "url": "https://finnhub.io/api/news?id=8ce88e961b0924b0f3f80fe5fb0fbe0d5f55dcbe323228953f67ca2d1a242c9b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Goldman Sachs just handed Microsoft its most coveted endorsement while cutting three other tech giants loose, and the reasoning behind that trade reveals exactly where Wall Street thinks the AI money flows next.",
                "category": "company",
                "datetime": 1785857644,
                "headline": "Goldman Sachs Just Added Microsoft to Its Closely Watched ‘Conviction List.’ Broadcom and ServiceNow Were Removed."
              },
              {
                "id": 141109951,
                "url": "https://finnhub.io/api/news?id=e797e0aa936de6b0064211ba2903917ac54b6d9e07c6a92e8357299462acd0fb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Merck (MRK) and Pfizer (PFE) raised their respective full-year sales outlooks on Tuesday, as both ph",
                "category": "company",
                "datetime": 1785855413,
                "headline": "Merck, Pfizer Lift Full-Year Sales Outlooks Following Second-Quarter Beats"
              },
              {
                "id": 141111550,
                "url": "https://finnhub.io/api/news?id=de33b8a0123d2b292054ba1f29716341249c010c55f9d5ee0e321353a5057f28",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2212125572/image_2212125572.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "OPKO Health's Q2 results: IP revenue surged on Nicoya deal and FY2026 guidance rose. Click for this OPK stock update.",
                "category": "company",
                "datetime": 1785851748,
                "headline": "OPKO Health: Mazdutide And MDX-2201 Could Change Everything"
              },
              {
                "id": 141108571,
                "url": "https://finnhub.io/api/news?id=5708ecdf4b3cffa8897a821239050597bee1821e59a7a11656e55d41c2d635fc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "NEW BRUNSWICK, N.J., August 04, 2026--Johnson & Johnson (NYSE: JNJ) today announced that Jennifer Taubert will retire from her position as Executive Vice President, Worldwide Chairman, Innovative Medicine following a distinguished career and over 21-year tenure at Johnson & Johnson. Under her leadership, the Company’s Innovative Medicine business grew to more than $60 billion in annual revenue and strengthened its position as one of the most respected and successful pharmaceutical businesses in",
                "category": "company",
                "datetime": 1785847500,
                "headline": "Johnson & Johnson’s Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September"
              },
              {
                "id": 141108535,
                "url": "https://finnhub.io/api/news?id=dd522ccfc79f9a0408dc8d5e3ca0c23bfb8752440a674e2f82ab916145697e77",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "GS, JPM, TRV and JNJ stand out as Dow hits a new high amid an AI-driven tech sell-off, with these blue-chip stocks backed by strong earnings growth.",
                "category": "company",
                "datetime": 1785844440,
                "headline": "4 Non-Tech Stocks to Grab as Dow Hits New Milestone Amid AI Sell-off"
              },
              {
                "id": 141109952,
                "url": "https://finnhub.io/api/news?id=c196a0a51c6c206f4c0014d5c01da2c4d468a664ae870902b3399777d9edc983",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Jennifer Taubert will step down after a lengthy run leading J&J’s pharmaceutical business. Elsewhere, pricing issues hampered what Wall Street analysts view as an otherwise strong gene therapy launch.",
                "category": "company",
                "datetime": 1785838800,
                "headline": "J&J pharma leader to retire; Krystal slumps on gene therapy miss"
              },
              {
                "id": 141105564,
                "url": "https://finnhub.io/api/news?id=66f2581ce869a0dc50dbf5c776861d1536aba6698cdf3389c7e283f6dce99fb9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Medicare quietly pockets a chunk of your Social Security before it ever reaches you, and the gap between what you expect and what you receive keeps widening every year. Three ETFs target that exact shortfall with income built to arrive on a schedule.",
                "category": "company",
                "datetime": 1785814558,
                "headline": "Medicare Now Takes $202.90 a Month Straight From Your Social Security Check. These 3 ETFs Pay It Back"
              },
              {
                "id": 141104215,
                "url": "https://finnhub.io/api/news?id=f90be4844bbfd3be905a623ee6e1e0773889b20041c5133207617d9f83f6a119",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The pharmaceutical giant sent shareholders a fortune in cash, yet the stock itself fell far behind the market. Here is the honest accounting of what owners actually got.",
                "category": "company",
                "datetime": 1785798877,
                "headline": "$49 Billion In Payouts, A Lagging Stock: The Pfizer Trade-Off"
              },
              {
                "id": 141102901,
                "url": "https://finnhub.io/api/news?id=d4dad4b699c25939294901b37ea777c978aeb76e6fceb2ae6fa35fdbcd0e2d11",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "SKYRIZI supplies close to a third of guided company revenue, which puts an unusual amount of AbbVie's future behind one patent estate.",
                "category": "company",
                "datetime": 1785791142,
                "headline": "AbbVie's Growth Now Leans On A Single Molecule"
              },
              {
                "id": 141102756,
                "url": "https://finnhub.io/api/news?id=a8910cf117021c61cc69007c4b44c3c275bc9664317da9ec3d5425c05a034996",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Stock Market Today: The Dow Jones index pops as oil stocks lag amid Trump Iran moves. Amazon clears a milestone. A Cathie Wood trade pays off.",
                "category": "company",
                "datetime": 1785790885,
                "headline": "Stock Market Today: Dow Rises To Record As Amazon Jumps; This Cathie Wood Trade Nets $2.9 Mil (Live Coverage)"
              },
              {
                "id": 141102934,
                "url": "https://finnhub.io/api/news?id=a7b5ef52a443eff1f0ea6384ec0cd328258e70aa2b8a85cd8fc38ed6cbff4d7f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) received FDA authorization for its OTTAVA robotic surgical system. The company is moving ahead with the commercial launch of OTTAVA as its first table integrated, soft tissue robotic platform. This marks Johnson & Johnson's entry into the competitive surgical robotics market with a differentiated system design. For investors watching Johnson & Johnson, the OTTAVA approval adds a new dimension to the MedTech story. Surgical robotics has become a focus area for...",
                "category": "company",
                "datetime": 1785780542,
                "headline": "Johnson & Johnson (JNJ) Gets FDA Nod For OTTAVA As It Enters Surgical Robotics"
              },
              {
                "id": 141102903,
                "url": "https://finnhub.io/api/news?id=1616416f52964b33626780df4bbf688e25cb5403a3309b1f71b9e4583bd1f513",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Amgen, Pfizer, Eli Lilly, Merck and Novo Nordisk are set to report Q2 results this week after a strong start for pharma earnings. Which names could beat forecasts?",
                "category": "company",
                "datetime": 1785778200,
                "headline": "Are These 5 Pharma Stocks Set to Surpass Q2 Earnings Forecasts?"
              },
              {
                "id": 141099051,
                "url": "https://finnhub.io/api/news?id=ad9d450feda6978d6c374b0689e9bc8e63f8464d5cc0bfbb4f8587674ef3c471",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Stock Market Today: The Dow Jones index rallies 600 points Monday as Trump calls off new U.S. strikes on Iran. Oil prices plunge.",
                "category": "company",
                "datetime": 1785776738,
                "headline": "Stock Market Today: Dow Jumps 600 Points On Trump Strikes Reversal; Oil Prices Plunge (Live Coverage)"
              },
              {
                "id": 141100145,
                "url": "https://finnhub.io/api/news?id=c3effdf47636ff5cbe8c243812847c1cb7215361a84c36afbba1e09ca9287946",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "JNJ",
                "summary": "Wondering what's happening in today's session for the dow jones index? Stay informed with the top movers within the dow jones index on Monday.",
                "category": "company",
                "datetime": 1785775204,
                "headline": "Top dow jones movers in Monday's session"
              },
              {
                "id": 141111662,
                "url": "https://finnhub.io/api/news?id=6e71450bdf5b7604e689e41936a1f88574d1e3d7cf4c5df85452b935df8a116d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "As the NASDAQ-100 corrects amid an AI CapEx-driven tech sell-off, sectors like healthcare and financials are rallying, boosting diversified value ETFs like the Schwab U.S. Large-Cap Value ETF (SCHV).",
                "category": "company",
                "datetime": 1785775200,
                "headline": "The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure"
              },
              {
                "id": 141100758,
                "url": "https://finnhub.io/api/news?id=1fe4262aec53041e30e95b49bb59431431aa3c75be0b85361ae2d41750573abc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Jim Cramer celebrated a dramatic pivot in market sentiment surrounding Johnson & Johnson (NYSE:JNJ) during Mad Money’s July 23 episode. After days of urging investors to accumulate the stock following a strong earnings report that Wall Street initially dismissed, Cramer highlighted the FDA approval of JNJ’s OTTAVA Robotic Surgical System as the catalyst that finally […]",
                "category": "company",
                "datetime": 1785774831,
                "headline": "Jim Cramer Analyzes Johnson & Johnson (JNJ) After Surgical Robotics Milestone"
              },
              {
                "id": 141100727,
                "url": "https://finnhub.io/api/news?id=93beca83add4b02ad8b271b7b1ba0242659fa4ae9be591f4bd91c8198b9827db",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The FTSE 100 index closed down 10.35 points, 0.1%, at 10,857.70.",
                "category": "company",
                "datetime": 1785773653,
                "headline": "Stocks mixed as AstraZeneca merger talk dents FTSE 100"
              },
              {
                "id": 141100760,
                "url": "https://finnhub.io/api/news?id=8f1b915fc3132e82d62fe8a26f06ddf2fbb9a0f7a0c014645a89f9f5aec61e87",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "J&J's oncology business posted strong Q2 growth as Darzalex, Erleada and newer cancer drugs boosted sales and advanced its long-term ambitions.",
                "category": "company",
                "datetime": 1785770400,
                "headline": "J&J's Strong Q2 Oncology Performance Fuels Future Growth Hopes"
              },
              {
                "id": 141100761,
                "url": "https://finnhub.io/api/news?id=7b92ac9f780895129eea930a6651202fe06c8fc6ae0dee90844ddfa38d9415cc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Medical sector earnings are off to a strong start, and four biotech companies are positioned to potentially beat estimates in upcoming quarterly results.",
                "category": "company",
                "datetime": 1785767640,
                "headline": "4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates"
              },
              {
                "id": 141100762,
                "url": "https://finnhub.io/api/news?id=2ea27cbf3abd8a393d2bc0318e479aa50e518982a54ac1f755402a8c71d35edc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (NYSE:JNJ) outlined its commercialization plans for the OTTAVA robotic surgical system after receiving U.S. Food and Drug Administration De Novo authorization, positioning the table-integrated platform as a long-term growth initiative in surgical robotics. The company said it",
                "category": "company",
                "datetime": 1785765877,
                "headline": "Johnson & Johnson’s OTTAVA Robotic Surgery System Targets Long-Term Growth"
              },
              {
                "id": 141100530,
                "url": "https://finnhub.io/api/news?id=951135ed0932f37386cd978a55b3a3388d0ac97a7aca343f35d07a35ed58f993",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) Discusses FDA Authorization and Market Introduction of OTTAVA Robotic Surgical System August 3, 2026 8:00 AM EDTCompany...",
                "category": "company",
                "datetime": 1785764994,
                "headline": "Johnson & Johnson (JNJ) Discusses FDA Authorization and Market Introduction of OTTAVA Robotic Surgical System Transcript"
              },
              {
                "id": 141100763,
                "url": "https://finnhub.io/api/news?id=0be540e82a1d9078f70e63b638cca9fa1d0c64a3cea7e9a3c62f3e6a4b2764df",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Here is how Avantor, Inc. (AVTR) and Johnson & Johnson (JNJ) have performed compared to their sector so far this year.",
                "category": "company",
                "datetime": 1785764402,
                "headline": "Are Medical Stocks Lagging  Avantor (AVTR) This Year?"
              },
              {
                "id": 141100764,
                "url": "https://finnhub.io/api/news?id=f7fdc53420181995471be2896364852b33008672ced4cf8fdbceaf6fc59c4022",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "The average brokerage recommendation (ABR) for Johnson & Johnson (JNJ) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",
                "category": "company",
                "datetime": 1785763803,
                "headline": "Is It Worth Investing in Johnson & Johnson (JNJ) Based on Wall Street's Bullish Views?"
              },
              {
                "id": 141098919,
                "url": "https://finnhub.io/api/news?id=bd9b5649a16451ecd7a4464d4d39dffad95926ad5902728055c64fcf700e6a84",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced the appointment of Michael J. Grissinger to its Board of Directors, effective August 3, 2026.",
                "category": "company",
                "datetime": 1785758400,
                "headline": "Lipocine Appoints Michael J. Grissinger to Board of Directors"
              },
              {
                "id": 141098920,
                "url": "https://finnhub.io/api/news?id=efa064f1c87fd57aa7321023e82d37ed432bbe23bffac7b6c5a9ab8d2184a849",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Former President of Intra-Cellular Therapies, Inc. was instrumental in building and scaling the company, which was subsequently acquired by Johnson & Johnson Experienced executive with a proven track record of guiding pharmaceutical companies through late-stage clinical development and commercialization Appointed as Helus Pharma prepares for topline data readout from APPROACH, the first pivotal Phase 3 Study of HLP003 as an adjunctive treatment for Major Depressive Disorder (“MDD”), expected in",
                "category": "company",
                "datetime": 1785757200,
                "headline": "Helus Pharma Appoints Michael Halstead as Chief Executive Officer"
              },
              {
                "id": 141098784,
                "url": "https://finnhub.io/api/news?id=6d5dea5d514acf65b00583fd0a8cc0080a09578686e11220b95315049c260bed",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Investing.com -- Goldman Sachs reshuffled its U.S. Conviction List in its August update, adding Microsoft and five other names while removing Broadcom and three others.",
                "category": "company",
                "datetime": 1785754815,
                "headline": "Microsoft joins, Broadcom exits Goldman’s top-stocks list"
              },
              {
                "id": 141100249,
                "url": "https://finnhub.io/api/news?id=d657bbe08cf729d6c34440968a1f7e51a7a1b8bac909ef32c5143ee090f93e62",
                "image": "",
                "source": "Benzinga",
                "related": "JNJ",
                "summary": "Wells Fargo  analyst Larry Biegelsen   maintains Johnson & Johnson (NYSE:JNJ) with a Overweight and raises the price target from $272 to $282.",
                "category": "company",
                "datetime": 1785750810,
                "headline": "Wells Fargo Maintains Overweight on Johnson & Johnson, Raises Price Target to $282"
              },
              {
                "id": 141094761,
                "url": "https://finnhub.io/api/news?id=ff17a12937b465c62b9ffdbfeafbfe8bcbb3519c118fb10cc656d891a14897d5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "As stocks pull back from recent highs, lean into these three blue chip dividend stocks.",
                "category": "company",
                "datetime": 1785697500,
                "headline": "3 Dividend Stocks That Are No-Brainer Buys for the Second Half of 2026"
              },
              {
                "id": 141093367,
                "url": "https://finnhub.io/api/news?id=36cc055b6e63a228111c23f91f75744f2d0f6552373efdf45201d4fedf9aeaf0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "After spending years and hundreds of millions of dollars, Johnson and Johnson has won FDA approval for its new surgical robot Ottava. Can it challenge the dominance of competitors who entered the race years earlier, or is the market already spoken for?",
                "category": "company",
                "datetime": 1785672480,
                "headline": "This Surgical Robot Could Transform the Operating Room"
              },
              {
                "id": 141089501,
                "url": "https://finnhub.io/api/news?id=b940b917f9a8df54f65a6bbcba221b1e64a2df04fc02072e36734c94b0bda2c9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "They have a combined 181 years of consecutive payout increases.",
                "category": "company",
                "datetime": 1785615300,
                "headline": "3 Dividend Stocks to Buy and Hold Forever"
              },
              {
                "id": 141087253,
                "url": "https://finnhub.io/api/news?id=475b5e956649ef734f1fb96237d15a9cc9124a92a44b1f15c4ad7f896dc6279b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Price targets on Johnson & Johnson have been moving higher, with bullish analysts now citing a range from about US$260 to US$305. This shift is closely linked to recent Street commentary that highlights solid execution in new medicines and MedTech, along with reduced legal uncertainty around talc litigation. As you read on, you will see how these changing targets fit into the broader analyst narrative and what to watch to stay on top of the story. Stay updated as the Fair Value for Johnson &...",
                "category": "company",
                "datetime": 1785586274,
                "headline": "Johnson & Johnson (JNJ) Stock Sees Modest Fair Value Lift After Analyst Target Increases"
              },
              {
                "id": 141084282,
                "url": "https://finnhub.io/api/news?id=d98eeb6acc0d178b622f018c3e03710d8dadd6b3634bc4098c2769cdc1d8958d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "JNJ",
                "summary": "Johnson & Johnson (JNJ) just issued one of the weirdest profit warnings in health care. The biotech business decreased its 2026 adjusted earnings guidance to between $10.96 and $11.11 a share, from a range of $11.60 to $11.75. This year, the newly closed acquisition of Firefly Bio and the ...",
                "category": "company",
                "datetime": 1785546180,
                "headline": "J&J’s biotech progress could punish its 2027 profit"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 3,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.9,
            "source_article_count": 179,
            "discarded_article_count": 159
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 19,
        "grade": "一般",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 2.1,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 2.1,
            "vcp_reason": "波幅收縮(11.7%→6.9%)；站上MA50；升放量(近10日2日)；Ready=N；Confirm=N",
            "vcp_metrics": {
              "up_days": 6,
              "vol_ref": 6988880,
              "down_days": 3,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 6415390,
              "avg_vol_20": 6450010,
              "avg_vol_30": 6988880,
              "range_pct_10": 0.06943761258462998,
              "range_pct_20": 0.09791235290907091,
              "range_pct_30": 0.11653183688050271,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": true,
              "down_shrink_ok": false,
              "up_expand_days": 2,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.9179425029475395,
              "dist_to_20d_high": 0.03841281151662035,
              "down_shrink_days": 1,
              "breakout_level_20d": 276.47,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.5958681716811399
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 1.2
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 2,
            "details": {
              "atrPct": 1.9054729394217436,
              "turnoverUsdM": 2058.07705486497,
              "liquidityPoints": 0.8,
              "volatilityPoints": 1.2
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.JNJ",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 255.7186,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 2.5,
              "rsi_score": 2,
              "macd_score": 1.5,
              "volume_score": 2
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.3,
            "stop_loss_percent": 3.8,
            "take_profit_price": 279.1425,
            "target_multiplier": 1.9,
            "technical_strength": 1.85,
            "take_profit_percent": 5
          },
          "positionPoints": 2,
          "stopLossPoints": 2.4,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.3120102355054586,
          "stopLossPercent": 3.810945878843487,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 78.57,
    "atr": {
      "atr": 5.0657,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 8,
      "atr_pct": 1.91
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "平衡",
      "score": 6,
      "value": 24.13
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "輕微流入",
      "score": 6,
      "value": 0.1866
    },
    "kdj": {
      "d": 57.08,
      "j": 8.36,
      "k": 40.84,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "平衡",
      "score": 6,
      "value": 55.84
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 6,
      "trend": "有流入",
      "value": 87588903,
      "recentSlope": 106630.3,
      "previousSlope": 2694970
    },
    "rsi": 57.43,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 260.7649,
      "position": "SAR喺價下",
      "distancePct": 1.91,
      "previousTrend": "上升"
    },
    "ma50": 258.8922,
    "macd": {
      "macd": 3.3239928627753557,
      "trend": "中性偏多",
      "signal": 3.74788263431401,
      "histogram": -0.42388977153865426
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 10,
      "value": 264.4298,
      "position": "連續5日>VWAP",
      "consecutiveAbove": 19
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "有量",
      "ratio": 1.2,
      "score": 6,
      "avgVolume": 6430270,
      "currentVolume": 7741497
    },
    "derived": {
      "ma20": 264.699,
      "ma50": 258.8922,
      "prevClose": 268.04,
      "avgVolume10": 6637990,
      "avgVolume20": 6430270,
      "changePercent": -0.82,
      "avgVolumeForScore": 6430270
    },
    "ma_cross": {
      "ma20": 264.699,
      "ma50": 258.8922,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 264.127,
      "prevMa50": 258.143,
      "spreadPct": 2.24,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 253.2884,
      "upper": 276.1096,
      "position": "上半部"
    },
    "rsi_short": 35.1,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 1.2
    }
  }
}

{
  "close": 265.85,
  "volume": 7741497,
  "changePercent": -0.82
}